

2



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C12N 15/55, 9/16, C12P 21/08, C12N 15/11		A1	(11) International Publication Number: WO 94/28144 (43) International Publication Date: 8 December 1994 (08.12.94)
(21) International Application Number:	PCT/US94/06066		(74) Agent: NOLAND, Greta, E.; Marshall, O'Toole, Gerstein, Murray & Borun, 6300 Sears Tower, 233 South Wacker Drive, Chicago, IL 60606 (US).
(22) International Filing Date:	27 May 1994 (27.05.94)		
(30) Priority Data:	08/068,051	27 May 1993 (27.05.93)	US
(71) Applicant:	BOARD OF REGENTS OF THE UNIVERSITY OF WASHINGTON [USUS]; A Public Institution of Higher Education, University of Washington, Seattle, WA 98105 (US).		(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(72) Inventors:	BEAVO, Joseph, A.; 6405 N.E. 188th Street, Seattle, WA 98155 (US). CORBIN, Jackie, D.; 710 Cantrell Avenue, Nashville, TN 37215 (US). FERGUSON, Kenneth, M.; 23221 14th Place West, Bothell, WA 98021 (US). FRANCIS, Sharron, H.; 4350 Chickering Lane, Nashville, TN 37215 (US). KADLECEK, Ann; 840 Midvale Avenue, Seattle, WA 98103 (US). LOUGHNEY, Kate; 7301 34th Avenue, N.E., Seattle, WA 98115 (US). McALLISTER-LUCAS, Linda, M.; 2704 Acklen Avenue, Nashville, TN 37212 (US). SONNENBURG, William, K.; 5704 236th S.W., Mountlake Terrace, WA 98043 (US). THOMAS, Melissa, K.; 1 Longfellow Place, Boston, MA 02114 (US).		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: CYCLIC GMP-BINDING, CYCLIC GMP-SPECIFIC PHOSPHODIESTER MATERIALS AND METHODS

PHOSPHORYLATION SITE

(92)



(57) Abstract

The present invention provides novel purified and isolated nucleotide sequences encoding the cGMP-binding, cGMP-specific phosphodiesterase designated cGB-PDE. Also provided by the invention are methods and materials for the recombinant production of cGB-PDE polypeptide products and methods for identifying compounds which modulate the enzymatic activity of cGB-PDE polypeptides.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

WO 94/28144

-1-

PCT/US94/06066

CYCLIC GMP-BINDING, CYCLIC GMP-SPECIFIC PHOSPHODIESTERASE MATERIALS AND METHODS

This application is a continuation-in-part of co-pending U.S. Patent Application Serial No. 08/068,051 filed May 27, 1993.

5 Experimental work described herein was supported in part by Research Grants GM15731, DK21723, DK40029 and GM41269 and the Medical Scientist Training Program Grant GM07347 awarded by the National Institutes of Health. The United States government has certain rights in the invention.

FIELD OF THE INVENTION

10 The present invention relates generally to a cyclic guanosine monophosphate-binding, cyclic guanosine monophosphate-specific phosphodiesterase designated cGB-PDE and more particularly to novel purified and isolated polynucleotides encoding cGB-PDE polypeptides, to methods and materials for recombinant production of cGB-PDE polypeptides, and to methods for identifying modulators of cGB-PDE activity.

BACKGROUND

20 Cyclic nucleotide phosphodiesterases (PDEs) that catalyze the hydrolysis of 3'5' cyclic nucleotides such as cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP) to the corresponding nucleoside 5' monophosphates constitute a complex family of enzymes. By mediating the intracellular concentration of the cyclic nucleotides, the PDE isoenzymes function in signal transduction pathways involving cyclic nucleotide second messengers.

25 A variety of PDEs have been isolated from different tissue sources and many of the PDEs characterized to date exhibit differences in biological properties including physicochemical properties, substrate specificity, sensitivity to inhibitors, immunological reactivity and mode of regulation. [See Beavo *et al.*, *Cyclic Nucleotide Phosphodiesterases: Structure, Regulation and Drug Action*, John Wiley & Sons, Chichester, U.K. (1990)] Comparison of the known amino acid sequences of various PDEs indicates that most PDEs are chimeric multidomain proteins that

WO 94/28144

PCT/US94/06066

-2-

have distinct catalytic and regulatory domains. [See Charbonneau, pp. 267-296 in Beavo *et al.*, *supra*] All mammalian PDEs characterized to date share a sequence of approximately 250 amino acid residues in length that appears to comprise the catalytic site and is located in the carboxyl terminal region of the enzyme. PDE domains that interact with allosteric or regulatory molecules are thought to be located within the amino-terminal regions of the isoenzymes. Based on their biological properties, the PDEs may be classified into six general families: the Ca^{2+} /calmodulin-stimulated PDEs (Type I), the cGMP-stimulated PDEs (Type II), the cGMP-inhibited PDEs (Type III), the cAMP-specific PDEs (Type IV), the cGMP-specific phosphodiesterase cGB-PDE (Type V) which is the subject of the present invention and the cGMP-specific photoreceptor PDEs (Type VI).

The cGMP-binding PDEs (Type II, Type V and Type VI PDEs), in addition to having a homologous catalytic domain near their carboxyl terminus, have a second conserved sequence which is located closer to their amino terminus and which may comprise an allosteric cGMP-binding domain. See Charbonneau *et al.*, *Proc. Natl. Acad. Sci. USA*, 87: 288-292 (1990).

The Type II cGMP-stimulated PDEs (cGs-PDEs) are widely distributed in different tissue types and are thought to exist as homodimers of 100-105 kDa subunits. The cGs-PDEs respond under physiological conditions to elevated cGMP concentrations by increasing the rate of cAMP hydrolysis. The amino acid sequence of a bovine heart cGs-PDE and a partial cDNA sequence of a bovine adrenal cortex cGS-PDE are reported in LeTrong *et al.*, *Biochemistry*, 29: 10280-10288 (1990) and full length bovine adrenal and human fetal brain cGB-PDE cDNA sequences are described in Patent Cooperation Treaty International Publication No. WO 92/18541 published on October 29, 1992. The full length bovine adrenal cDNA sequence is also described in Sonnenburg *et al.*, *J. Biol. Chem.*, 266: 17655-17661 (1991).

The photoreceptor PDEs and the cGB-PDE have been described as cGMP-specific PDEs because they exhibit a 50-fold or greater selectivity for hydrolyzing cGMP over cAMP.

The photoreceptor PDEs are the rod outer segment PDE (ROS-PDE) and the cone PDE (COS-PDE). The holoenzyme structure of the ROS-PDE consists of two large subunits α (88 kDa) and β (84 kDa) which are both catalytically active

WO 94/28144

PCT/US94/06066

-3-

and two smaller γ regulatory subunits (both 11 kDa). A soluble form of the ROS-PDE has also been identified which includes α , β , and γ subunits and a δ subunit (15 kDa) that appears to be identical to the COS-PDE 15 kDa subunit. A full-length cDNA corresponding to the bovine membrane-associated ROS-PDE α subunit is described in Ovchinnikov *et al.*, *FEBS Lett.*, 223: 169-173 (1987) and a full length cDNA corresponding to the bovine rod outer segment PDE β subunit is described in Lipkin *et al.*, *J. Biol. Chem.*, 265: 12955-12959 (1990). Ovchinnikov *et al.*, *FEBS Lett.*, 204: 169-173 (1986) presents a full-length cDNA corresponding to the bovine ROS-PDE γ subunit and the amino acid sequence of the δ subunit. Expression of the ROS-PDE has also been reported in brain in Collins *et al.*, *Genomics*, 13: 698-704 (1992). The COS-PDE is composed of two identical α' (94 kDa) subunits and three smaller subunits of 11 kDa, 13 kDa and 15 kDa. A full-length cDNA corresponding to the bovine COS-PDE α' subunit is reported in Li *et al.*, *Proc. Natl. Acad. Sci. USA*, 87: 293-297 (1990).

cGB-PDE has been purified to homogeneity from rat [Francis *et al.*, *Methods Enzymol.*, 159: 722-729 (1988)] and bovine lung tissue [Thomas *et al.*, *J. Biol. Chem.*, 265: 14964-14970 (1990), hereinafter "Thomas I"]. The presence of this or similar enzymes has been reported in a variety of tissues and species including rat and human platelets [Harnet *et al.*, *Adv. Cyclic Nucleotide Protein Phosphorylation Res.*, 16: 119-136 (1984)], rat spleen [Coquil *et al.*, *Biochem. Biophys. Res. Commun.*, 127: 226-231 (1985)], guinea pig lung [Davis *et al.*, *J. Biol. Chem.*, 252: 4078-4084 (1977)], vascular smooth muscle [Coquil *et al.*, *Biochim. Biophys. Acta*, 631: 148-165 (1980)], and sea urchin sperm [Francis *et al.*, *J. Biol. Chem.*, 255: 620-626 (1979)]. cGB-PDE may be a homodimer comprised of two 93 kDa subunits. [See Thomas I, *supra*] cGB-PDE has been shown to contain a single site not found in other known cGMP-binding PDEs which is phosphorylated by cGMP-dependent protein kinase (cGK) and, with a lower affinity, by cAMP-dependent protein kinase (cAK). [See Thomas *et al.*, *J. Biol. Chem.*, 265: 14971-14978 (1990), hereinafter "Thomas II"] The primary amino acid sequence of the phosphorylation site and of the amino-terminal end of a fragment generated by chymotryptic digestion of cGB-PDE are described in Thomas II, *supra*, and Thomas

WO 94/28144

PCT/US94/06066

-4-

I, *supra*, respectively. However, the majority of the amino acid sequence of cGB-PDE has not previously been described.

Various inhibitors of different types of PDEs have been described in the literature. Two inhibitors that exhibit some specificity for Type V PDEs are 5 zaprinast and dipyridamole. See Francis *et al.*, pp. 117-140 in Beavo *et al.*, *supra*.

Elucidation of the DNA and amino acid sequences encoding the cGB-PDE and production of cGB-PDE polypeptide by recombinant methods would provide information and material to allow the identification of novel agents that selectively modulate the activity of the cGB-PDEs. The recognition that there are distinct types 10 or families of PDE isoenzymes and that different tissues express different complements of PDEs has led to an interest in the development of PDE modulators which may have therapeutic indications for disease states that involve signal transduction pathways utilizing cyclic nucleotides as second messengers. Various selective and non-selective inhibitors of PDE activity are discussed in Murray *et al.*, 15 *Biochem. Soc. Trans.*, 20(2): 460-464 (1992). Development of PDE modulators without the ability to produce a specific PDE by recombinant DNA techniques is difficult because all PDEs catalyze the same basic reaction, have overlapping substrate specificities and occur only in trace amounts. As a result, purification to homogeneity of many PDEs is a tedious and difficult process.

20 There thus continues to exist a need in the art for DNA and amino acid sequence information for the cGB-PDE, for methods and materials for the recombinant production of cGB-PDE polypeptides and for methods for identifying specific modulators of cGB-PDE activity.

SUMMARY OF THE INVENTION

25 The present invention provides novel purified and isolated polynucleotides (e.g., DNA sequences and RNA transcripts, both sense and antisense strands, including splice variants thereof) encoding the cGMP-binding, cGMP-specific PDE designated cGB-PDE. Preferred DNA sequences of the invention include genomic and cDNA sequences as well as wholly or partially chemically synthesized 30 DNA sequences. DNA sequences encoding cGB-PDE that are set out in SEQ ID NO: 9 or 20 and DNA sequences which hybridize thereto under stringent conditions

WO 94/28144

PCT/US94/06066

-5-

or DNA sequences which would hybridize thereto but for the redundancy of the genetic code are contemplated by the invention. Also contemplated by the invention are biological replicas (i.e., copies of isolated DNA sequences made *in vivo* or *in vitro*) of DNA sequences of the invention. Autonomously replicating recombinant 5 constructions such as plasmid and viral DNA vectors incorporating cGB-PDE sequences and especially vectors wherein DNA encoding cGB-PDE is operatively linked to an endogenous or exogenous expression control DNA sequence and a transcriptional terminator are also provided. Specifically illustrating expression 10 plasmids of the invention is the plasmid hcgbmet156-2 6n in *E. coli* strain JM109 which was deposited with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland 20852, on May 4, 1993 as Accession No. 15 69296.

According to another aspect of the invention, host cells including 15 procaryotic and eucaryotic cells, are stably transformed with DNA sequences of the invention in a manner allowing the desired polypeptides to be expressed therein. Host cells expressing cGB-PDE products can serve a variety of useful purposes. Such cells constitute a valuable source of immunogen for the development of antibody substances 20 specifically immunoreactive with cGB-PDE. Host cells of the invention are conspicuously useful in methods for the large scale production of cGB-PDE polypeptides wherein the cells are grown in a suitable culture medium and the desired 25 polypeptide products are isolated from the cells or from the medium in which the cells are grown by, for example, immunoaffinity purification.

cGB-PDE products may be obtained as isolates from natural cell 25 sources or may be chemically synthesized, but are preferably produced by recombinant procedures involving host cells of the invention. Use of mammalian host cells is expected to provide for such post-translational modifications (e.g., glycosylation, truncation, lipidation and tyrosine, serine or threonine phosphorylation) 30 as may be needed to confer optimal biological activity on recombinant expression products of the invention. cGB-PDE products of the invention may be full length polypeptides, fragments or variants. Variants may comprise cGB-PDE polypeptide analogs wherein one or more of the specified (i.e., naturally encoded) amino acids is deleted or replaced or wherein one or more nonspecified amino acids are added:

WO 94/28144

PCT/US94/06066

-6-

(1) without loss of one or more of the biological activities or immunological characteristics specific for cGB-PDE; or (2) with specific disablement of a particular biological activity of cGB-PDE.

Also comprehended by the present invention are antibody substances (e.g., monoclonal and polyclonal antibodies, single chain antibodies, chimeric antibodies, CDR-grafted antibodies and the like) and other binding proteins specific for cGB-PDE. Specific binding proteins can be developed using isolated or recombinant cGB-PDE or cGB-PDE variants or cells expressing such products. Binding proteins are useful, in turn, in compositions for immunization as well as for purifying cGB-PDE polypeptides and detection or quantification of cGB-PDE polypeptides in fluid and tissue samples by known immunological procedures. They are also manifestly useful in modulating (i.e., blocking, inhibiting or stimulating) biochemical activities of cGB-PDE, especially those activities involved in signal transduction. Anti-idiotypic antibodies specific for anti-cGB-PDE antibody substances are also contemplated.

The scientific value of the information contributed through the disclosures of DNA and amino acid sequences of the present invention is manifest. As one series of examples, knowledge of the sequence of a cDNA for cGB-PDE makes possible the isolation by DNA/DNA hybridization of genomic DNA sequences encoding cGB-PDE and specifying cGB-PDE expression control regulatory sequences such as promoters, operators and the like. DNA/DNA hybridization procedures carried out with DNA sequences of the invention under stringent conditions are likewise expected to allow the isolation of DNAs encoding allelic variants of cGB-PDE, other structurally related proteins sharing one or more of the biochemical and/or immunological properties specific to cGB-PDE, and non-human species proteins homologous to cGB-PDE. Polynucleotides of the invention when suitably labelled are useful in hybridization assays to detect the capacity of cells to synthesize cGB-PDE. Polynucleotides of the invention may also be the basis for diagnostic methods useful for identifying a genetic alteration(s) in the cGB-PDE locus that underlies a disease state or states. Also made available by the invention are anti-sense polynucleotides relevant to regulating expression of cGB-PDE by those cells which ordinarily express the same.

WO 94/28144

PCT/US94/06066

-7-

The DNA and amino acid sequence information provided by the present invention also makes possible the systematic analysis of the structure and function of cGB-PDE and definition of those molecules with which it will interact. Agents that modulate cGB-PDE activity may be identified by incubating a putative modulator with lysate from eucaryotic cells expressing recombinant cGB-PDE and determining the effect of the putative modulator on cGB-PDE phosphodiesterase activity. In a preferred embodiment the eucaryotic cell lacks endogenous cyclic nucleotide phosphodiesterase activity. Specifically illustrating such a eucaryotic cell is the yeast strain YKS45 which was deposited with the ATCC on May 19, 1993 as Accession No. 74225. The selectivity of a compound that modulates the activity of the cGB-PDE can be evaluated by comparing its activity on the cGB-PDE to its activity on other PDE isozymes. The combination of the recombinant cGB-PDE products of the invention with other recombinant PDE products in a series of independent assays provides a system for developing selective modulators of cGB-PDE.

Selective modulators may include, for example, antibodies and other proteins or peptides which specifically bind to the cGB-PDE or cGB-PDE nucleic acid, oligonucleotides which specifically bind to the cGB-PDE or cGB-PDE nucleic acid and other non-peptide compounds (e.g., isolated or synthetic organic molecules) which specifically react with cGB-PDE or cGB-PDE nucleic acid. Mutant forms of cGB-PDE which affect the enzymatic activity or cellular localization of the wild-type cGB-PDE are also contemplated by the invention. Presently preferred targets for the development of selective modulators include, for example: (1) the regions of the cGB-PDE which contact other proteins and/or localize the cGB-PDE within a cell, (2) the regions of the cGB-PDE which bind substrate, (3) the allosteric cGMP-binding site(s) of cGB-PDE, (4) the phosphorylation site(s) of cGB-PDE and (5) the regions of the cGB-PDE which are involved in dimerization of cGB-PDE subunits. Modulators of cGB-PDE activity may be therapeutically useful in treatment of a wide range of diseases and physiological conditions.

WO 94/28144

PCT/US94/06066

-8-

BRIEF DESCRIPTION OF THE DRAWINGS

Numerous other aspects and advantages of the present invention will be apparent upon consideration of the following detailed description thereof, reference being made to the drawing wherein:

5 FIGURE 1A to 1C is an alignment of the conserved catalytic domains of several PDE isoenzymes wherein residues which are identical in all PDEs listed are indicated by their one letter amino acid abbreviation in the "conserved" line, residues which are identical in the cGB-PDE and photoreceptor PDEs only are indicated by a star in the "conserved" line and gaps introduced for optimum alignment are indicated by periods;

10 FIGURE 2A to 2C is an alignment of the cGMP-binding domains of several PDE isoenzymes wherein residues which are identical in all PDEs listed are indicated by their one letter amino acid abbreviation in the "conserved" line and gaps introduced for optimum alignment are indicated by periods;

15 FIGURE 3 is an alignment of internally homologous repeats from several PDE isoenzymes wherein residues identical in each repeat A and B from all cGMP-binding PDEs listed are indicated by their one letter amino acid abbreviation in the "conserved" line and stars in the "conserved" line represent positions in which all residues are chemically conserved;

20 FIGURE 4 schematically depicts the domain organization of cGB-PDE;

FIGURE 5 is a bar graph representing the results of experiments in which extracts of COS cells transfected with bovine cGB-PDE sequences or extracts of untransfected COS cells were assayed for phosphodiesterase activity using either 20 μ M cGMP or 20 μ M cAMP as the substrate;

25 FIGURE 6 is a graph depicting results of assays of extracts from cells transfected with bovine cGB-PDE sequences for cGMP phosphodiesterase activity in the presence of a series of concentrations of phosphodiesterase inhibitors including dipyridamole (closed squares), zaprinast (closed circles), methoxymethylxanthine (closed triangles) and rolipram (open circles);

30 FIGURE 7 is a bar graph presenting results of experiments in which cell extracts from COS cells transfected with bovine cGB-PDE sequences or control

WO 94/28144

PCT/US94/06066

-9-

untransfected COS cells were assayed for [³H]cGMP-binding activity in the absence (-) or presence (+) of 0.2 mM IBMX; and

5 FIGURE 8 is a graph of the results of assays in which extracts from cells transfected with bovine cGB-PDE sequences were assayed for [³H]cGMP-binding activity in the presence of excess unlabelled cAMP (open circles) or cGMP (closed circles) at the concentrations indicated.

DETAILED DESCRIPTION

The following examples illustrate the invention. Example 1 describes the isolation of a bovine cGB-PDE cDNA fragment by PCR and subsequent isolation of a full length cGB-PDE cDNA using the PCR fragment as a probe. Example 2 presents an analysis of the relationship of the bovine cGB-PDE amino acid sequence to sequences reported for various other PDEs. Northern blot analysis of cGB-PDE mRNA in various bovine tissues is presented in Example 3. Expression of the bovine cGB-PDE cDNA in COS cells is described in Example 4. Example 5 presents results of assays of the cGB-PDE COS cell expression product for phosphodiesterase activity, cGMP-binding activity and Zn²⁺ hydrolase activity. Example 6 describes the isolation of human cDNAs homologous to the bovine cGB-PDE cDNA. The expression of a human cGB-PDE cDNA in yeast cells is presented in Example 7. RNase protection assays to detect cGB-PDE in human tissues are described in Example 8. Example 9 describes the bacterial expression of human cGB-PDE cDNA and the development of antibodies reactive with the bacterial cGB-PDE expression product. Example 10 describes cGB-PDE analogs and fragments. The generation of monoclonal antibodies that recognize cGB-PDE is described in Example 11. Example 12 relates to utilizing recombinant cGB-PDE products of the invention to develop agents that selectively modulate the biological activities of cGB-PDE.

Example 1

The polymerase chain reaction (PCR) was utilized to isolate a cDNA fragment encoding a portion of cGB-PDE from bovine lung first strand cDNA. Fully degenerate sense and antisense PCR primers were designed based on the partial cGB-

WO 94/28144

PCT/US94/06066

-10-

PDE amino acid sequence described in Thomas I, *supra*, and novel partial amino acid sequence information.

A. Purification of cGB-PDE Protein

5 cGB-PDE was purified as described in Thomas I, *supra*, or by a modification of that method as described below.

Fresh bovine lungs (5-10 kg) were obtained from a slaughterhouse and immediately placed on ice. The tissue was ground and combined with cold PEM buffer (20mM sodium phosphate, pH 6.8, containing 2mM EDTA and 25mM β -mercaptoethanol). After homogenization and centrifugation, the resulting supernatant 10 was incubated with 4-7 liters of DEAE-cellulose (Whatman, UK) for 3-4 hours. The DEAE slurry was then filtered under vacuum and rinsed with multiple volumes of cold PEM. The resin was poured into a glass column and washed with three to four volumes of PEM. The protein was eluted with 100mM NaCl in PEM and twelve 1-liter fractions were collected. Fractions were assayed for IBMX-stimulated cGMP 15 binding and cGMP phosphodiesterase activities by standard procedures described in Thomas *et al.*, *supra*. Appropriate fractions were pooled, diluted 2-fold with cold, deionized water and subjected to Blue Sepharose[®] CL-6B (Pharmacia LKB Biotechnology Inc., Piscataway, NJ) chromatography. Zinc chelate affinity adsorbent chromatography was then performed using either an agarose or Sepharose-based gel 20 matrix. The resulting protein pool from the zinc chelation step treated as described in the Thomas I, *supra*, or was subjected to a modified purification procedure.

As described in Thomas I, *supra*, the protein pool was applied in multiple loads to an HPLC Bio-Sil TSK-545 DEAE column (150 x 21.5 mm) (BioRad Laboratories, Hercules, CA) equilibrated in PEM at 4°C. After an equilibration 25 period, a 120-ml wash of 50mM NaCl in PEM was followed by a 120-ml linear gradient (50-200mM NaCl in PEM) elution at a flow rate of 2 ml/minute. Appropriate fractions were pooled and concentrated in dialysis tubing against Sephadex G-200 (Boehringer Mannheim Biochemicals, UK) to a final volume of 1.5 ml. The concentrated cGB-PDE pool was applied to an HPLC gel filtration column 30 (Bio-Sil TSK-250, 500 x 21.5 mm) equilibrated in 100mM sodium phosphate, pH 6.8, 2mM EDTA, 25mM β -mercaptoethanol and eluted with a flow rate of 2 ml/minute at 4°C.

WO 94/28144

PCT/US94/06066

-11-

If the modified, less cumbersome procedure was performed, the protein pool was dialyzed against PEM for 2 hours and loaded onto a 10 ml preparative DEAE Sephadex column (Pharmacia) equilibrated in PEM buffer. The protein was eluted batchwise with 0.5M NaCl in PEM, resulting in an approximately 10-15 fold concentration of protein. The concentrated protein sample was loaded onto an 800 ml (2.5 cm x 154 cm) Sephadex S400 gel filtration column (Boehringer) equilibrated in 0.1M NaCl in PEM, and eluted at a flow rate of 1.7 ml/minute.

The purity of the protein was assessed by Coomassie staining after sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Approximately 0.5-3.0 mg of pure cGB-PDE were obtained per 10 kg bovine lung.

Rabbit polyclonal antibodies specific for the purified bovine cGB-PDE were generated by standard procedures.

B. Amino Acid Sequencing of cGB-PDE

cGB-PDE phosphorylated with [³²P]ATP and was then digested with protease to yield ³²P-labelled phosphopeptides. Approximately 100 µg of purified cGB-PDE was phosphorylated in a reaction mixture containing 9mM MgCl₂, 9µM [³²P]ATP, 10µM cGMP, and 4.2 µg purified bovine catalytic subunit of cAMP-dependent protein kinase (cAK) in a final volume of 900 µl. Catalytic subunit of cAK was prepared according to the method of Flockhart *et al.*, pp. 209-215 in Marangos *et al.*, *Brain Receptor Methodologies, Part A*, Academic Press, Orlando, Florida (1984). The reaction was incubated for 30 minutes at 30°C, and stopped by addition of 60 µl of 200mM EDTA.

To obtain a first peptide sequence from cGB-PDE, 3.7 µl of a 1 mg/ml solution of a α -chymotrypsin in KPE buffer (10mM potassium phosphate, pH 6.8, with 2mM EDTA) was added to 100 µg purified, phosphorylated cGB-PDE and the mixture was incubated for 30 minutes at 30°C. Proteolysis was stopped by addition of 50 µl of 10% SDS and 25 µl of β -mercaptoethanol. The sample was boiled until the volume was reduced to less than 400 µl, and was loaded onto an 8% preparative SDS-polyacrylamide gel and subjected to electrophoresis at 50mAmps. The separated digestion products were electroblotted onto Immobilon polyvinylidene difluoride (Millipore, Bedford, MA), according to the method of Matsudaira, *J. Biol. Chem.*, 262: 10035-10038 (1987). Transferred protein was identified by Coomassie Blue

WO 94/28144

PCT/US94/06066

-12-

staining, and a 50 kDa band was excised from the membrane for automated gas-phase amino acid sequencing. The sequence of the peptide obtained by the α -chymotryptic digestion procedure is set out below as SEQ ID NO: 1.

SEQ ID NO: 1

5

REXDANRINMYAQYVKNTM

A second sequence was obtained from a cGB-PDE peptide fragment generated by V8 proteolysis. Approximately 200 μ g of purified cGB-PDE was added to 10mM MgCl₂, 10 μ M [³²P]ATP, 100 μ M cGMP, and 1 μ g/ml purified catalytic subunit of cAK in a final volume of 1.4 ml. The reaction was incubated for 30 minutes at 30°C, and was terminated by the addition of 160 μ l of 0.2M EDTA. Next, 9 μ l of 1 mg/ml *Staphylococcal aureus* V8 protease (International Chemical Nuclear Biomedicals, Costa Mesa, CA) diluted in KPE was added, followed by a 15 minute incubation at 30°C. Proteolysis was stopped by addition of 88 μ l of 10% SDS and 45 μ l β -mercaptoethanol. The digestion products were separated by electrophoresis on a preparative 10% SDS-polyacrylamide gel run at 25 mAmps for 4.5 hours. Proteins were electroblotted and stained as described above. A 28 kDa protein band was excised from the membrane and subjected to automated gas-phase amino acid sequencing. The sequence obtained is set out below as SEQ ID NO: 2.

10

SEQ ID NO: 2

15

QSLAAAVVP

C. PCR Amplification of Bovine cDNA

The partial amino acid sequences utilized to design primers (SEQ ID NO: 3, below, and amino acids 9-20 of SEQ ID NO: 1) and the sequences of the corresponding PCR primers (in IUPAC nomenclature) are set below wherein SEQ ID NO: 3 is the sequence reported in Thomas I, *supra*.

20

SEQ ID NO: 3

F D N D E G E Q

5' TTY GAY AAY GAY GAR GGN GAR CA 3' (SEQ ID NO: 4)

3' AAR CTR TTR CTR CTY CCN CTY GT 5' (SEQ ID NO: 5)

WO 94/28144

PCT/US94/06066

-13-

SEQ ID NO: 1, Amino acids 9-20

N Y M Y A Q Y V K N T M

5' AAY TAY ATG TAY GCN CAR TAY GT 3' (SEQ ID NO: 6)

3' TTR ATR TAC ATR CGN GTY ATR CA 5' (SEQ ID NO: 7)

3' TTR ATR TAC ATR CGN GTY ATR CAN TTY TTR TGN TAC 5'
(SEQ ID NO: 8)

The sense and antisense primers, synthesized using an Applied Biosystems Model 380A DNA Synthesizer (Foster City, CA), were used in all possible combinations to amplify cGB-PDE-specific sequences from bovine lung first strand cDNA as described below.

After ethanol precipitation, pairs of oligonucleotides were combined (SEQ ID NO: 4 or 5 combined with SEQ ID NOs: 6, 7 or 8) at 400nM each in a PCR reaction. The reaction was run using 50 ng first strand bovine lung cDNA (generated using AMV reverse transcriptase and random primers on oligo dT selected bovine lung mRNA), 200 μ M dNTPs, and 2 units of Taq polymerase. The initial denaturation step was carried out at 94°C for 5 minutes, followed by 30 cycles of a 1 minute denaturation step at 94°C, a two minute annealing step at 50°C, and a 2 minute extension step at 72°C. PCR was performed using a Hybaid Thermal Reactor (ENK Scientific Products, Saratoga, CA) and products were separated by gel electrophoresis on a 1% low melting point agarose gel run in 40mM Tris-acetate, 2mM EDTA. A weak band of about 800-840 bp was seen with the primers set out in SEQ ID NOs: 4 and 7 and with primers set out in SEQ ID NOs: 4 and 8. None of the other primer pairs yielded visible bands. The PCR product generated by amplification with the primers set out in SEQ ID NOs: 4 and 7 was isolated using the Gene Clean® (Bio101, La Jolla, CA) DNA purification kit according to the manufacturer's protocol. The PCR product (20 ng) was ligated into 200 ng of linearized pBluescript KS(+) (Stratagene, La Jolla, CA), and the resulting plasmid construct was used to transform *E. coli* XL1 Blue cells (Stratagene Cloning Systems, La Jolla, CA). Putative transformation positives were screened by sequencing. The sequences obtained were not homologous to any known PDE sequence or to the known partial cGB-PDE sequences.

WO 94/28144

PCT/US94/06066

-14-

PCR was performed again on bovine lung first strand cDNA using the primers set out in SEQ ID NOs: 4 and 7. A clone containing a 0.8 Kb insert with a single large open reading frame was identified. The open reading frame encoded a polypeptide that included the amino acids KNTM (amino acids 17-20 of SEQ ID NO: 1 which were not utilized to design the primer sequence which is set out in SEQ ID NO: 7) and that possessed a high degree of homology to the deduced amino acid sequences of the cGs-, ROS- and COS-PDEs. The clone identified corresponds to nucleotides 489-1312 of SEQ ID NO: 9.

5
10 D. Construction and Hybridization Screening
of a Bovine cDNA Library

In order to obtain a cDNA encoding a full-length cGB-PDE, a bovine lung cDNA library was screened using the ^{32}P -labelled PCR-generated cDNA insert as a probe.

15 Polyadenylated RNA was prepared from bovine lung as described Sonnenburg et al., *J. Biol. Chem.*, 266: 17655-17661 (1991). First strand cDNA was synthesized using AMV reverse transcriptase (Life Sciences, St. Petersburg, FL) with random hexanucleotide primers as described in Ausubel et al., *Current Protocols in Molecular Biology*, John Wiley & Sons, New York (1987). Second strand cDNA was synthesized using *E. coli* DNA polymerase I in the presence of *E. coli* DNA
20 ligase and *E. coli* RNase H. Selection of cDNAs larger than 500 bp was performed by Sepharose[®] CL-4B (Millipore) chromatography. *Eco*RI adaptors (Promega, Madison, WI) were ligated to the cDNA using T4 DNA ligase. Following heat inactivation of the ligase, the cDNA was phosphorylated using T4 polynucleotide kinase. Unligated adaptors were removed by Sepharose[®] CL-4B chromatography
25 (Pharmacia, Piscataway, NJ). The cDNA was ligated into *Eco*RI-digested, dephosphorylated lambda Zap[®]II arms (Stratagene) and packaged with Gigapack[®] Gold (Stratagene) extracts according to the manufacturer's protocol. The titer of the unamplified library was 9.9×10^5 with 18% nonrecombinants. The library was amplified by plating 50,000 plaque forming units (pfu) on to twenty 150 mm plates,
30 resulting in a final titer of 5.95×10^6 pfu/ml with 21% nonrecombinants.

The library was plated on twenty-four 150 mm plates at 50,000 pfu/plate, and screened with the ^{32}P -labelled cDNA clone. The probe was prepared

WO 94/28144

PCT/US94/06066

-15-

using the method of Feinberg *et al.*, *Anal. Biochem.*, 137: 266-267 (1984), and the ³²P-labelled DNA was purified using Elutip-D® columns (Schleicher and Schuell Inc., Keene, NH) using the manufacturer's protocol. Plaque-lifts were performed using 15 cm nitrocellulose filters. Following denaturation and neutralization, DNA was 5 fixed onto the filters by baking at 80°C for 2 hours. Hybridization was carried out at 42°C overnight in a solution containing 50% formamide, 5X SSC (0.75M NaCl, 0.75M sodium citrate, pH 7), 25mM sodium phosphate (pH 7.0), 2X Denhardt's solution, 10% dextran sulfate, 90 µg/ml yeast tRNA, and approximately 10⁶ cpm/ml ³²P-labelled probe (5x10⁸ cpm/µg). The filters were washed twice in 0.1X SSC, 10 0.1% SDS at room temperature for 15 minutes per wash, followed by a single 20 minute wash in 0.1X SSC, 1% SDS at 45°C. The filters were then exposed to X-ray film at -70°C for several days.

Plaques that hybridized with the labelled probe were purified by several 15 rounds of replating and rescreening. Insert cDNAs were subcloned into the pBluescript SK(-) vector (Stratagene) by the *in vivo* excision method described by the manufacturer's protocol. Southern blots were performed in order to verify that the rescued cDNA hybridized to the PCR probe. Putative cGB-PDE cDNAs were sequenced using Sequenase® Version 2.0 (United States Biochemical Corporation, Cleveland, Ohio) or TaqTrack® kits (Promega).

20 Three distinct cDNA clones designated cGB-2, cGB-8 and cGB-10 were isolated. The DNA and deduced amino acid sequences of clone cGB-8 are set out in SEQ ID NOS: 9 and 10. The DNA sequence downstream of nucleotide 2686 may represent a cloning artifact. The DNA sequence of cGB-10 is identical to the sequence of cGB-8 with the exception of one nucleotide. The DNA sequence of 25 clone cGB-2 diverges from that of clone cGB-8 5' to nucleotide 219 of clone cgb-8 (see SEQ ID NO: 9) and could encode a protein with a different amino terminus.

30 The cGB-8 cDNA clone is 4474 bp in length and contains a large open reading frame of 2625 bp. The triplet ATG at position 99-101 in the nucleotide sequence is predicted to be the translation initiation site of the cGB-PDE gene because it is preceded by an in-frame stop codon and the surrounding bases are compatible with the Kozak consensus initiation site for eucaryotic mRNAs. The stop codon TAG is located at positions 2724-2726, and is followed by 1748 bp of 3' untranslated

WO 94/28144

PCT/US94/06066

-16-

sequence. The sequence of cGB-8 does not contain a transcription termination consensus sequence, therefore the clone may not represent the entire 3' untranslated region of the corresponding mRNA.

5 The open reading frame of the cGB-8 cDNA encodes an 875 amino acid polypeptide with a calculated molecular mass of 99.5 kD. This calculated molecular mass is only slightly larger than the reported molecular mass of purified cGB-PDE, estimated by SDS-PAGE analysis to be approximately 93 kDa. The deduced amino acid sequence of cGB-8 corresponded exactly to all peptide sequences obtained from purified bovine lung cGB-PDE providing strong evidence that cGB-8
10 encodes cGB-PDE.

Example 2

15 A search of the SWISS-PROT and GEnEmbl data banks (Release of February, 1992) conducted using the FASTA program supplied with the Genetics Computer Group (GCG) Software Package (Madison, Wisconsin) revealed that only DNA and amino acid sequences reported for other PDEs displayed significant similarity to the DNA and deduced amino acid of clone cGB-8.

20 Pairwise comparisons of the cGB-PDE deduced amino acid sequence with the sequences of eight other PDEs were conducted using the ALIGN [Dayhoff *et al.*, *Methods Enzymol.*, 92: 524-545 (1983)] and BESTFIT [Wilbur *et al.*, *Proc. Natl. Acad. Sci. USA*, 80: 726-730 (1983)] programs. Like all mammalian phosphodiesterases sequenced to date, cGB-PDE contains a conserved catalytic domain sequence of approximately 250 amino acids in the carboxyl-terminal half of the protein that is thought to be essential for catalytic activity. This segment comprises amino acids 578-812 of SEQ ID NO: 9 and exhibits sequence conservation
25 with the corresponding regions of other PDEs. Table 1 below sets out the specific identity values obtained in pairwise comparisons of other PDEs with amino acids 578-812 of cGB-PDE, wherein "ratdunce" is the rat cAMP-specific PDE; "61 kCaM" is the bovine 61 kDa calcium/calmodulin-dependent PDE; "63 kCaM" is the bovine 63 kDa calcium/calmodulin-dependent PDE; "drosdunce" is the drosophila cAMP-specific dunce PDE; "ROS- α " is the bovine ROS-PDE α -subunit; "ROS- β " is the
30

WO 94/28144

PCT/US94/06066

-17-

bovine ROS-PDE β -subunit; "COS- α' " is the bovine COS-PDE α' subunit; and "cGs" is the bovine cGs-PDE (612-844).

Table 1

	<u>Phosphodiesterase</u>	<u>Catalytic Domain Residues</u>	<u>% Identity</u>
5	Ratdunce	77-316	31
	61 kCaM	193-422	29
	63 kcam	195-424	29
	drosdunce	1-239	28
	ROS- α	535-778	45
10	ROS- β	533-776	46
	COS- α'	533-776	48
	cGs	612-844	40

Multiple sequence alignments were performed using the Progressive Alignment Algorithm [Feng *et al.*, *Methods Enzymol.*, 183: 375-387 (1990)] implemented in the PILEUP program (GCG Software). FIGURE 1A to 1C shows a multiple sequence alignment of the proposed catalytic domain of cGB-PDE with the all the corresponding regions of the PDEs of Table 1. Twenty-eight residues (see residues indicated by one letter amino acid abbreviations in the "conserved" line on FIGURE 1A to 1C) are invariant among the isoenzymes including several conserved histidine residues predicted to play a functional role in catalysis. See Charbonneau *et al.*, *Proc. Natl. Acad. Sci. USA, supra*. The catalytic domain of cGB-PDE more closely resembles the catalytic domains of the ROS-PDEs and COS-PDEs than the corresponding regions of other PDE isoenzymes. There are several conserved regions among the photoreceptor PDEs and cGB-PDE that are not shared by other PDEs. Amino acid positions in these regions that are invariant in the photoreceptor PDE and cGB-PDE sequences are indicated by stars in the "conserved" line of FIGURE 1A to 1C. Regions of homology among cGB-PDE and the ROS- and COS-PDEs may serve important roles in conferring specificity for cGMP hydrolysis relative to cAMP hydrolysis or for sensitivity to specific pharmacological agents.

WO 94/28144

PCT/US94/06066

-18-

Sequence similarity between cGB-PDE, cGs-PDE and the photoreceptor PDEs, is not limited to the conserved catalytic domain but also includes the noncatalytic cGMP binding domain in the amino-terminal half of the protein. Optimization of the alignment between cGB-PDE, cGs-PDE and the photoreceptor PDEs indicates that an amino-terminal conserved segment may exist including amino acids 142-526 of SEQ ID NO: 9. Pairwise analysis of the sequence of the proposed cGMP-binding domain of cGB-PDE with the corresponding regions of the photoreceptor PDEs and cGs-PDE revealed 26-28% sequence identity. Multiple sequence alignment of the proposed cGMP-binding domains with the cGMP-binding PDEs is shown in FIGURE 2A to 2C wherein abbreviations are the same as indicated for Table 1. Thirty-eight positions in this non-catalytic domain appear to be invariant among all cGMP-binding PDEs (see positions indicated by one letter amino acid abbreviations in the "conserved" line of FIGURE 2A to 2C).

The cGMP-binding domain of the cGMP-binding PDEs contains internally homologous repeats which may form two similar but distinct inter- or intra-subunit cGMP-binding sites. FIGURE 3 shows a multiple sequence alignment of the repeats a (corresponding to amino acids 228-311 of cGB-PDE) and b (corresponding to amino acids 410-500 of cGB-PDE) of the cGMP-binding PDEs. Seven residues are invariant in each A and B regions (see residues indicated by one letter amino acid abbreviations in the "conserved" line of FIGURE 3). Residues that are chemically conserved in the A and B regions are indicated by stars in the "conserved" line of FIGURE 3. cGMP analog studies of cGB-PDE support the existence of a hydrogen bond between the cyclic nucleotide binding site on cGB-PDE and the 2'OH of cGMP.

Three regions of cGB-PDE have no significant sequence similarity to other PDE isoenzymes. These regions include the sequence flanking the carboxyl-terminal end of the catalytic domain (amino acids 812-875), the sequence separating the cGMP-binding and catalytic domains (amino acids 527-577) and the amino-terminal sequence spanning amino acids 1-141. The site (the serine at position 92 of SEQ ID NO: 10) of phosphorylation of cGB-PDE by cGK is located in this amino-terminal region of sequence. Binding of cGMP to the allosteric site on cGB-PDE is required for its phosphorylation.

WO 94/28144

PCT/US94/06066

-19-

A proposed domain structure of cGB-PDE based on the foregoing comparisons with other PDE isoenzymes is presented in FIGURE 4. This domain structure is supported by the biochemical studies of cGB-PDE purified from bovine lung.

5

Example 3

The presence of cGB-PDE mRNA in various bovine tissues was examined by Northern blot hybridization.

Polyadenylated RNA was purified from total RNA preparations using the Poly(A) Quick® mRNA purification kit (Stratagene) according to the manufacturer's protocol. RNA samples (5 µg) were loaded onto a 1.2% agarose, 6.7% formaldehyde gel. Electrophoresis and RNA transfer were performed as previously described in Sonnenburg *et al.*, *supra*. Prehybridization of the RNA blot was carried out for 4 hours at 45°C in a solution containing 50% formamide, 5X SSC, 25mM sodium phosphate, pH 7, 2X Denhardt's solution, 10% dextran sulfate, and 0.1 mg/ml yeast tRNA. A random hexanucleotide-primer-labelled probe (5 X 10⁸ cpm/µg) was prepared as described in Feinberg *et al.*, *supra*, using the 4.7 kb cGB-8 cDNA clone of Example 2 excised by digestion with *Acc*I and *Sac*II. The probe was heat denatured and injected into a blotting bag (6 X 10⁵ cpm/ml) following prehybridization. The Northern blot was hybridized overnight at 45°C, followed by one 15 minute wash with 2X SSC, 0.1% SDS at room temperature, and three 20 minute washes with 0.1X SSC, 0.1% SDS at 45°C. The blot was exposed to X-ray film for 24 hours at -70°C. The size of the RNA that hybridized with the cGB-PDE probe was estimated using a 0.24-9.5 kb RNA ladder that was stained with ethidium bromide and visualized with UV light.

25

The ³²P-labelled cGB-PDE cDNA hybridized to a single 6.8 kb bovine lung RNA species. A mRNA band of the identical size was also detected in polyadenylated RNA isolated from bovine trachea, aorta, kidney and spleen.

Example 4

The cGB-PDE cDNA in clone cGB-8 of Example 2 was expressed in COS-7 cells (ATCC CRL1651).

WO 94/28144

PCT/US94/06066

-20-

A portion of the cGB-8 cDNA was isolated following digestion with the restriction enzyme *Xba*I. *Xba*I cut at a position in the pBluescript polylinker sequence located 30 bp upstream of the 5' end of the cGB-8 insert and at position 3359 within the cGB-8 insert. The resulting 3389 bp fragment, which contains the entire coding region of cGB-8, was then ligated into the unique *Xba*I cloning site of the expression vector pCDM8 (Invitrogen, San Diego, CA). The pCDM8 plasmid is a 4.5 kb eucaryotic expression vector containing a cytomegalovirus promoter and enhancer, an SV40-derived origin of replication, a polyadenylation signal, a procaryotic origin of replication (derived from pBR322) and a procaryotic genetic marker (supF). *E. coli* MC1061/P3 cells (Invitrogen) were transformed with the resulting ligation products, and transformation positive colonies were screened for proper orientation of the cGB-8 insert using PCR and restriction enzyme analysis. The resulting expression construct containing the cGB-8 insert in the proper orientation is referred to as pCDM8-cGB-PDE.

The pCDM8-cGB-PDE DNA was purified from large-scale plasmid preparations using Qiagen pack-500 columns (Chatsworth, CA) according to the manufacturer's protocol. COS-7 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum, 50 μ g/ml penicillin and 50 μ g/ml streptomycin at 37°C in a humidified 5% CO₂ atmosphere. Approximately 24 hours prior to transfection, confluent 100 mm dishes of cells were replated at one-fourth or one-fifth the original density. In a typical transfection experiment, cells were washed with buffer containing 137mM NaCl, 2.7mM KCl, 1.1mM potassium phosphate, and 8.1mM sodium phosphate, pH 7.2 (PBS). Then 4-5 ml of DMEM containing 10% NuSerum (Collaborative Biomedical Products, Bedford, MA) was added to each plate. Transfection with 10 μ g pCDM8-cGB-PDE DNA or pCDM8 vector DNA mixed with 400 μ g DEAE-dextran (Pharmacia) in 60 μ l TBS [Tris-buffered saline: 25mM Tris-HCl (pH 7.4), 137mM NaCl, 5mM KCl, 0.6mM Na₂HPO₄, 0.7mM CaCl₂, and 0.5mM MgCl₂] was carried out by dropwise addition of the mixture to each plate. The cells were incubated at 37°C, 5% CO₂ for 4 hours, and then treated with 10% dimethyl sulfoxide in PBS for 1 minute. After 2 minutes, the dimethyl sulfoxide was removed, the cells were washed with PBS and incubated in complete medium. After 48 hours, cells were suspended in 0.5-1 ml of cold

WO 94/28144

PCT/US94/06066

-21-

homogenization buffer [40mM Tris-HCl (pH 7.5), 15mM benzamidine, 15mM β -mercaptoethanol, 0.7 μ g/ml pepstatin A, 0.5 μ g/ml leupeptin, and 5 μ M EDTA] per plate of cells, and disrupted using a Dounce homogenizer. The resulting whole-cell extracts were assayed for phosphodiesterase activity, cGMP-binding activity, and total protein concentration as described below in Example 5.

5

Example 5

10 Phosphodiesterase activity in extracts of the transfected COS cells of Example 4 or in extracts of mock transfected COS cells was measured using a modification of the assay procedure described for the cGs-PDE in Martins *et al.*, *J. Biol. Chem.*, 257: 1973-1979 (1982). Cells were harvested and extracts prepared 48 hours after transfection. Incubation mixtures contained 40mM MOPS buffer (pH 7), 0.8mM EDTA, 15mM magnesium acetate, 2 mg/ml bovine serum albumin, 20 μ M [3 H]cGMP or [3 H]cAMP (100,000-200,000 cpm/assay) and COS-7 cell extract in a total volume of 250 μ l. The reaction mixture was incubated for 10 minutes at 30°C, and then stopped by boiling. Next, 10 μ l of 10mg/ml *Crotalus atrox* venom (Sigma) was added followed by a 10 minute incubation at 30°C. Nucleoside products were separated from unreacted nucleotides as described in Martins *et al.*, *supra*. In all studies, less than 15% of the total [3 H]cyclic nucleotide was hydrolyzed during the reaction.

15

20 The results of the assays are presented in FIGURE 5 wherein the results shown are averages of three separate transfections. Transfection of COS-7 cells with pCDM8-cGB-PDE DNA resulted in the expression of approximately 15-fold higher levels of cGMP phosphodiesterase activity than in mock-transfected cells or in cells transfected with pCDM8 vector alone. No increase in cAMP phosphodiesterase activity over mock or vector-only transfected cells was detected in extracts from cells transfected with pCDM8-cGB-PDE DNA. These results confirm that the cGB-PDE bovine cDNA encodes a cGMP-specific phosphodiesterase.

25

30

Extracts from the transfected COS cells of Example 4 were also assayed for cGMP PDE activity in the presence of a series of concentrations of the PDE inhibitors zaprinast, dipyridamole (Sigma), isobutyl-1-methyl-8-methoxymethylxanthine (MeOxMeMIX) and rolipram.

WO 94/28144

PCT/US94/06066

-22-

The results of the assays are presented in FIGURE 6 wherein PDE activity in the absence of inhibitor is taken as 100% and each data point represents the average of two separate determinations. The relative potencies of PDE inhibitors for inhibition of cGMP hydrolysis by the expressed cGB-BPDE cDNA protein product were identical to those relative potencies reported for native cGB-PDE purified from bovine lung (Thomas I, *supra*). IC₅₀ values calculated from the curves in FIGURE 6 are as follows: zaprinast (closed circles), 2 μ M; dipyridamole (closed squares), 3.5 μ M; MeOxMeMIX (closed triangles), 30 μ M; and rolipram (open circles), >300 μ M. The IC₅₀ value of zaprinast, a relatively specific inhibitor of cGMP-specific phosphodiesterases, was at least two orders of magnitude lower than that reported for inhibition of phosphodiesterase activity of the cGs-PDE or of the cGMP-inhibited phosphodiesterase (cGi-PDEs) (Reeves *et al.*, pp. 300-316 in Beavo *et al.*, *supra*). Dipyrimadole, an effective inhibitor of selected cAMP- and cGMP-specific phosphodiesterases, was also a potent inhibitor of the expressed cGB-PDE. The relatively selective inhibitor of calcium/calmodulin-stimulated phosphodiesterase (CaM-PDEs), MeOxMeMIX, was approximately 10-fold less potent than zaprinast and dipyridamole, in agreement with results using cGB-PDE activity purified from bovine lung. Rolipram, a potent inhibitor of low K_m cAMP phosphodisterases, was a poor inhibitor of expressed cGB-PDE cDNA protein product. These results show that the cGB-PDE cDNA encodes a phosphodiesterase that possesses catalytic activity characteristic of cGB-PDE isolated from bovine tissue, thus verifying the identity of the cGB-8 cDNA clone as a cGB-PDE.

It is of interest to note that although the relative potencies of the PDE inhibitors for inhibition of cGMP hydrolysis were identical for the recombinant and bovine isolate cGB-PDE, the absolute IC₅₀ values for all inhibitors tested were 2-7 fold higher for the recombinant cGB-PDE. This difference could not be attributed to the effects of any factors present in COS-7 cell extracts on cGMP hydrolytic activity, since cGB-PDE isolated from bovine tissue exhibited identical kinetics of inhibition as a pure enzyme, or when added back to extracts of mock-transfected COS-7 cells. This apparent difference in pharmacological sensitivity may be due to a subtle difference in the structure of the recombinant cGB-PDE cDNA protein product and bovine lung cGB-PDE, such as a difference in post-translational

WO 94/28144

PCT/US94/06066

-23-

modification at or near the catalytic site. Alternatively, this difference may be due to an alteration of the catalytic activity of bovine lung cGB-PDE over several purification steps.

Cell extracts were assayed for [³H]cGMP-binding activity in the absence or presence of 0.2mM 3-isobutyl-1-methylxanthine (IBMX) (Sigma), a competitive inhibitor of cGMP hydrolysis. The cGMP binding assay, modified from the assay described in Thomas I, *supra*, was conducted in a total volume of 80 μ l. Sixty μ l of cell extract was combined with 20 μ l of a binding cocktail such that the final concentration of components of the mixture were 1 μ M [³H]cGMP, 5 μ M cAMP, and 10 μ M 8-bromo-cGMP. The cAMP and 8-bromo-cGMP were added to block [³H]cGMP binding to cAK and cGK, respectively. Assays were carried out in the absence and presence of 0.2mM IBMX. The reaction was initiated by the addition of the cell extract, and was incubated for 60 minutes at 0°C. Filtration of the reaction mixtures was carried out as described in Thomas I, *supra*. Blanks were determined by parallel incubations with homogenization buffer replacing cell extracts, or with a 100-fold excess of unlabelled cGMP. Similar results were obtained with both methods. Total protein concentration of the cell extracts was determined by the method of Bradford, *Anal. Biochem.*, 72:248-254 (1976) using bovine serum albumin as the standard.

Results of the assay are set out in FIGURE 7. When measured at 1 μ M [³H]cGMP in the presence of 0.2mM IBMX, extracts from COS-7 cells transfected with pCDM8-cGB-PDE exhibited 8-fold higher cGMP-binding activity than extracts from mock-transfected cells. No IBMX stimulation of background cGMP binding was observed suggesting that little or no endogenous cGB-PDE was present in the COS-7 cell extracts. In extracts of pCDM8-cGB-PDE transfected cells cGMP-specific activity was stimulated approximately 1.8-fold by the addition of 0.2mM IBMX. The ability of IBMX to stimulate cGMP binding 2-5 fold is a distinctive property of the cGMP-binding phosphodiesterases.

Cell extracts were assayed as described above for [³H]cGMP-binding activity (wherein concentration of [³H]cGMP was 2.5 μ M) in the presence of excess unlabelled cAMP or cGMP. Results are presented in FIGURE 8 wherein cGMP binding in the absence of unlabelled competitor was taken as 100% and each data

WO 94/28144

PCT/US94/06066

-24-

5 point represents the average of three separate determinations. The binding activity of the protein product encoded by the cGB-PDE cDNA was specific for cGMP relative to cAMP. Less than 10-fold higher concentrations of unlabelled cGMP were required to inhibit [³H]cGMP binding activity by 50% whereas approximately 100-fold higher concentrations of cAMP were required for the same degree of inhibition.

10 The results presented in this example show that the cGB-PDE cDNA encodes a phosphodiesterase which possesses biochemical activities characteristic of native cGB-PDE.

15 The catalytic domains of mammalian PDEs and a *Drosophila* PDE contain two tandem conserved sequences (HX₃HX₂₄₋₂₆E) that are typical Zn²⁺-binding motifs in Zn²⁺ hydrolases such as thermolysin [Vallee and Auld, *Biochem.*, 29: 5647-5659 (1990)]. cGB-PDE binds Zn²⁺ in the presence of large excesses of Mg²⁺, Mn²⁺, Fe²⁺, Fe³⁺, Ca²⁺ or Cd²⁺. In the absence of added metal, cGB-PDE has a PDE activity that is approximately 20% of the maximum activity that occurs in the presence of 40 mM Mg²⁺, and this basal activity is inhibited by 1,10-phenanthroline or EDTA. This suggests that a trace metal(s) accounts for the basal PDE activity despite exhaustive treatments to remove metals. PDE activity is stimulated by addition of Zn²⁺ (0.02-1 μ M) or Co²⁺ (1-20 μ M), but not by Fe²⁺, Fe³⁺, Ca²⁺, Cd²⁺, or Cu²⁺. Zn²⁺ increases the basal PDE activity up to 70% of the maximum stimulation produced by 40mM Mg²⁺. The stimulatory effect of Zn²⁺ in these assays may be compromised by an inhibitory effect that is caused by Zn²⁺ concentrations >1 μ M. The Zn²⁺-supported PDE activity and Zn²⁺ binding by cGB-PDE occur at similar concentrations of Zn²⁺. cGB-PDE thus appears to be a Zn²⁺ hydrolase and Zn²⁺ appears to play a critical role in the activity of the enzyme. See, Colbran *et al.*,
20 *The FASEB J.*, 8: Abstract 2148 (March 15, 1994).

Example 6

30 Several human cDNA clones, homologous to the bovine cDNA clone encoding cGB-PDE, were isolated by hybridization under stringent conditions using a nucleic acid probe corresponding to a portion of the bovine cGB-8 clone (nucleotides 489-1312 of SEQ ID NO: 9).

WO 94/28144

PCT/US94/06066

-25-

Isolation of cDNA Fragments Encoding Human cGB-PDE

Three human cDNA libraries (two glioblastoma and one lung) in the vector lambda Zap were probed with the bovine cGB-PDE sequence. The PCR-generated clone corresponding to nucleotides 484-1312 of SEQ ID NO: 9 which is described in Example 1 was digested with *Eco*RI and *Sal*I and the resulting 0.8 kb cDNA insert was isolated and purified by agarose gel electrophoresis. The fragment was labelled with radioactive nucleotides using a random primed DNA labelling kit (Boehringer).

The cDNA libraries were plated on 150 mm petri plates at a density of approximately 50,000 plaques per plate. Duplicate nitrocellulose filter replicas were prepared. The prehybridization buffer was 3X SSC, 0.1% sarkosyl, 10X Denhardt's, 20mM sodium phosphate (pH 6.8) and 50 μ g/ml salmon testes DNA. Prehybridization was carried out at 65°C for a minimum of 30 minutes. Hybridization was carried out at 65°C overnight in buffer of the same composition with the addition of 1-5x10⁵ cpm/ml of probe. The filters were washed at 65°C in 2X SSC, 0.1% SDS. Hybridizing plaques were detected by autoradiography. The number of cDNAs that hybridized to the bovine probe and the number of cDNAs screened are indicated in Table 2 below.

Table 2

	<u>cDNA Library</u>	<u>Type</u>	<u>Positive Plaques</u>	<u>Plaques Screened</u>
20	Human SW 1088 glioblastoma	dT-primed	1	1.5x10 ⁶
	Human lung	dT-primed	2	1.5x10 ⁶
25	Human SW 1088 glioblastoma	dT-primed	4	1.5x10 ⁶

Plasmids designated cgbS2.1, cgbS3.1, cgbL23.1, cgbL27.1 and cgbS27.1 were excised *in vivo* from the lambda Zap clones and sequenced.

Clone cgbS3.1 contains 2060 bp of a PDE open reading frame followed by a putative intron. Analysis of clone cgbS2.1 reveals that it corresponds to clone

WO 94/28144

PCT/US94/06066

-26-

5 cgbS3.1 positions 664 to 2060 and extends the PDE open reading frame an additional 585 bp before reading into a putative intron. The sequences of the putative 5' untranslated region and the protein encoding portions of the cgbS2.1 and cgbS3.1 clones are set out in SEQ ID NOs: 11 and 12, respectively. Combining the two cDNAs yields a sequence containing approximately 2.7 kb of an open reading encoding a PDE. The three other cDNAs did not extend any further 5' or 3' than cDNA cgbS3.1 or cDNA cgbS2.1.

10 To isolate additional cDNAs, probes specific for the 5' end of clone cgbS3.1 and the 3' end of clone cgbS2.1 were prepared and used to screen a SW1088 glioblastoma cDNA library and a human aorta cDNA library. A 5' probe was derived from clone cgbS3.1 by PCR using the primers cgbS3.1S311 and cgbL23.1A1286 whose sequences are set out in SEQ ID NOs: 8 and 9, respectively, and below.

15 Primer cgbS3.1S311 (SEQ ID NO: 13)
5' GCCACCAGAGAAATGGTC 3'
Primer cgbL23.1A1286 (SEQ ID NO: 14)
5' ACAATGGGTCTAACAGAGGC 3'

20 The PCR reaction was carried out in a 50 ul reaction volume containing 50 pg cgbS3.1 cDNA, 0.2mM dNTP, 10 ug/ml each primer, 50 mM KCl, 10mM Tris-HCl pH 8.2, 1.5mM MgCl₂ and Taq polymerase. After an initial four minute denaturation at 94°C, 30 cycles of one minute at 94°C, two minutes at 50°C and four minutes at 72°C were carried out. An approximately 0.2 kb fragment was generated by the PCR reaction which corresponded to nucleotides 300-496 of clone cgbS3.1.

25 A 3' probe was derived from cDNA cgbS2.1 by PCR using the oligos cgbL23.1S1190 and cgbS2.1A231 whose sequences are set out below.

Primer cgbL23.1S1190 (SEQ ID NO: 15)
5' TCAGTGCATGTTGCTGC 3'
Primer cgbS2.1A231 (SEQ ID NO: 16)
5' TACAAACATGTTCATCAG 3'
30 The PCR reaction as carried out similarly to that described above for generating the 5' probe, and yielded a fragment of approximately 0.8kb corresponding to nucleotides

WO 94/28144

PCT/US94/06066

-27-

1358-2139 of cDNA cgbS2.1. The 3' 157 nucleotides of the PCR fragment (not shown in SEQ ID NO: 12) are within the presumptive intron.

The two PCR fragments were purified and isolated by agarose gel electrophoresis, and were labelled with radioactive nucleotides by random priming. 5 A random-primed SW1088 glioblastoma cDNA library (1.5×10^6 plaques) was screened with the labelled fragments as described above, and 19 hybridizing plaques were isolated. An additional 50 hybridizing plaques were isolated from a human aorta cDNA library (dT and random primed, Clontech, Palo Alto, CA).

10 Plasmids were excised *in vivo* from some of the positive lambda Zap clones and sequenced. A clone designated cgbS53.2, the sequence of which is set out in SEQ ID NO: 17, contains an approximately 1.1 kb insert whose sequence overlaps the last 61 bp of cgbS3.1 and extends the open reading frame an additional 135 bp beyond that found in cgbS2.1. The clone contains a termination codon and approximately 0.3 kB of putative 3' untranslated sequence.

15 Generation of a Composite cDNA Encoding Human cGB-PDE

Clones cgbS3.1, cgbS2.1 and cgbS53.2 were used as described in the following paragraphs to build a composite cDNA that contained a complete human cGB-PDE opening reading frame. The composite cDNA is designated cgbmet156-2 and was inserted in the yeast ADH1 expression vector pBNY6N.

20 First, a plasmid designated cgb stop-2 was generated that contained the 3' end of the cGB-PDE open reading frame. A portion of the insert of the plasmid was generated by PCR using clone cgbS53.2 as a template. The PCR primers utilized were cgbS2.1S1700 and cgbstop-2.

25 Primer cgbS2.1S1700 (SEQ ID NO: 18)

5' TTTGGAAGATCCTCATCA 3'

Primer cgbstop-2 (SEQ ID NO: 19)

5' ATGTCTCGAGTCAGTTCCGCTTGGCCTG 3'

The PCR reaction was carried out in 50 ul containing 50 pg template DNA, 0.2mM dNTPs, 20mM Tris-HCl pH 8.2, 10mM KC1, 6mM $(\text{NH}_4)_2\text{SO}_4$, 1.5mM MgCl₂, 30 0.1% Triton-X-100, 500ng each primer and 0.5 units of Pfu polymerase (Stratagene). The reaction was heated to 94°C for 4 minutes and then 30 cycles of 1 minute at 94°C, 2 minutes at 50°C and four minutes at 72°C were performed. The polymerase

WO 94/28144

PCT/US94/06066

-28-

was added during the first cycle at 50°C. The resulting PCR product was phenol/chloroform extracted, chloroform extracted, ethanol precipitated and cut with the restriction enzymes *BcII* and *XhoI*. The restriction fragment was purified on an agarose gel and eluted.

5 This fragment was ligated to the cDNA cgbS2.1 that had been grown in dam *E. coli*, cut with the restriction enzymes *BcII* and *XhoI*, and gel-purified using the Promega magic PCR kit. The resulting plasmid was sequenced to verify that cgbstop-2 contains the 3' portion of the cGB-PDE open reading frame.

10 Second, a plasmid carrying the 5' end of the human cGB-PDE open reading frame was generated. Its insert was generated by PCR using clone cgbS3.1 as a template. PCR was performed as described above using primers cgbmet156 and cgbS2.1A2150.

Primer cgbmet156 (SEQ ID NO: 20)

5' TACAGAATTCTGACCATGGAGCGGGCCGGC 3'

15 Primer cgbS2.1A2150 (SEQ ID NO: 21)

5' CATTCTAAGCGGATACAG 3'

20 The resulting PCR fragment was phenol/choloform extracted, choloform extracted, ethanol precipitated and purified on a Sepharose CL-6B column. The fragment was cut with the restriction enzymes *EcoRV* and *EcoRI*, run on an agarose gel and purified by spinning through glass wool. Following phenol/chloroform extraction, chloroform extraction and ethanol precipitation, the fragment was ligated into *EcoRI/EcoRV* digested BluescriptII SK(+) to generate plasmid cgbmet156. The DNA sequence of the insert and junctions was determined. The insert contains a new *EcoRI* site and an additional 5 nucleotides that together replace the original 155 nucleotides 5' of the initiation codon. The insert extends to an *EcoRV* site beginning 25 531 nucleotides from the initiation codon.

30 The 5' and 3' portions of the cGB-PDE open reading frame were then assembled in vector pBNY6a. The vector pBNY6a was cut with *EcoRI* and *XhoI*, isolated from a gel and combined with the agarose gel purified *EcoRI/EcoRV* fragment from cgbmet156 and the agarose gel purified *EcoRV/XhoI* fragment from cgbstop-2. The junctions of the insert were sequenced and the construct was named hcgbmet156-2 6a.

WO 94/28144

PCT/US94/06066

-29-

The cGB-PDE insert from hcgbmet156-2 6a was then moved into the expression vector pBNY6n. Expression of DNA inserted in this vector is directed from the yeast ADH1 promoter and terminator. The vector contains the yeast 2 micron origin of replication, the pUC19 origin of replication and an ampicillin resistance gene. Vector pBNY6n was cut with *Eco*RI and *Xba*I and gel-purified. The *Eco*RI/*Xba*I insert from hcgbmet156-2 6a was gel purified using Promega magic PCR columns and ligated into the cut pBNY6n. All new junctions in the resulting construct, hcgbmet156-2 6n, were sequenced. The DNA and deduced amino acid sequences of the insert of hcgbmet156-2 6n which encodes a composite human cGB-PDE is set out in SEQ ID NOS: 22 and 23. The insert extends from the first methionine in clone cgbS3.1 (nucleotide 156) to the stop codon (nucleotide 2781) in the composite cDNA. Because the methionine is the most 5' methionine in clone cgbS3.1 and because there are no stop codons in frame with the methionine and upstream of it, the insert in pBNY6n may represent a truncated form of the open reading frame.

Variant cDNAs

Four human cGB-PDE cDNAs that are different from the hcgbmet156-2 6n composite cDNA have been isolated. One cDNA, cgbL23.1, is missing an internal region of hcgbmet156-2 6n (nucleotides 997-1000 to 1444-1447). The exact end points of the deletion cannot be determined from the cDNA sequence at those positions. Three of the four variant cDNAs have 5' end sequences that diverge from the hcgbmet156-2 6n sequence upstream of nucleotide 151 (cDNAs cgbA7f, cgbA5C, cgbI2). These cDNAs presumably represent alternatively spliced or unspliced mRNAs.

Example 7

The composite human cGB-PDE cDNA construct, hcgbmet156-2 6n, was transformed into the yeast strain YKS45 (ATCC 74225) (MAT α his3 trp1 ura3 leu3 pde1::HIS3 pde2::TRP1) in which two endogenous PDE genes are deleted. Transformants complementing the leu^r deficiency of the YKS45 strain were selected and assayed for cGB-PDE activity. Extracts from cells bearing the plasmid hcgbmet156-2 6n were determined to display cyclic GMP-specific phosphodiesterase activity by the assay described below.

WO 94/28144

PCT/US94/06066

-30-

One liter of YKS45 cells transformed with the plasmid cgbmet156-2 6n and grown in SC-leu medium to a density of 1-2x10⁷ cells/ml was harvested by centrifugation, washed once with deionized water, frozen in dry ice/ethanol and stored at -70°C. Cell pellets (1-1.5 ml) were thawed on ice in the presence of an equal volume of 25mM Tris-Cl (pH 8.0)/5mM EDTA/5mM EGTA/1mM o-phenanthroline/0.5mM AEBSF (Calbiochem)/0.1% β -mercaptoethanol and 10 ug/ml each of aprotinin, leupeptin, and pepstatin A. The thawed cells were added to 2 ml of acid-washed glass beads (425-600 μ M, Sigma) in 15 ml Corex tube. Cells were broken with 4 cycles consisting of a 30 second vortexing on setting 1 followed by a 10 second incubation on ice. The cell lysate was centrifuged at 12,000 x g for 10 minutes and the supernatant was passed through a 0.8 μ filter. The supernatant was assayed for cGMP PDE activity as follows. Samples were incubated for 20 minutes at 30°C in the presence of 45mM Tris-Cl (pH 8.0), 2mM EGTA, 1mM EDTA, 0.2mg/ml BSA, 5mM MgCl₂, 0.2mM o-phenanthroline, 2ug/ml each of pepstatin A, 15 leupeptin, and aprotinin, 0.1mM AEBSF, 0.02% β -mercaptoethanol and 0.1mM [³H]cGMP as substrate. [¹⁴C]-AMP (0.5 nCi/assay) was added as a recovery standard. The reaction was terminated with stop buffer (0.1M ethanolamine pH 9.0, 0.5M ammonium sulfate, 10mM EDTA, 0.05% SDS final concentration). The product was separated from the cyclic nucleotide substrate by chromatography on BioRad Affi-Gel 20 601. The sample was applied to a column containing approximately 0.25 ml of Affi-Gel 601 equilibrated in column buffer (0.1M ethanolamine pH 9.0 containing 0.5M ammonium sulfate). The column was washed five times with 0.5 ml of column buffer. The product was eluted with four 0.5 ml aliquots of 0.25 acetic acid and mixed with 5 ml Ecolume (ICN Biochemicals). The radioactive product was 25 measured by scintillation counting.

Example 8

Analysis of expression of cGB-PDE mRNA in human tissues was carried out by RNase protection assay.

A probe corresponding to a portion of the putative cGMP binding domain of cGB-PDE (402 bp corresponding to nucleotides 1450 through 1851 of SEQ ID NO: 13) was generated by PCR. The PCR fragment was inserted into the EcoRI

WO 94/28144

PCT/US94/06066

-31-

site of the plasmid pBSII SK(-) to generate the plasmid RP3. RP3 plasmid DNA was linearized with *Xba*I and antisense probes were generated by a modification of the Stratagene T7 RNA polymerase kit. Twenty-five ng of linearized plasmid was combined with 20 microcuries of alpha ³²P rUTP (800 Ci/mmol, 10 mCi/ml), 1X 5 transcription buffer (40mM TrisCl, pH 8, 8mM MgCl₂, 2mM spermidine, 50mM NaCl), 0.25mM each rATP, rGTP and rCTP, 0.1 units of RNase Block II, 5mM DTT, 8μM rUTP and 5 units of T7 RNA Polymerase in a total volume of 5 μl. The reaction was allowed to proceed 1 hour at room temperature and then the DNA template was removed by digestion with RNase free DNase. The reaction was diluted 10 into 100 μl of 40mM TrisCl, pH 8, 6mM MgCl₂ and 10mM NaCl. Five units of RNase-free DNase were added and the reaction was allowed to continue another 15 minutes at 37°C. The reaction was stopped by a phenol extraction followed by a phenol chloroform extraction. One half volume of 7.5M NH₄OAc was added and the probe was ethanol precipitated.

15 The RNase protection assays were carried out using the Ambion RNase Protection kit (Austin, TX) and 10 μg RNA isolated from human tissues by an acid guanidinium extraction method. Expression of cGB-PDE mRNA was easily detected in RNA extracted from skeletal muscle, uterus, bronchus, skin, right saphenous vein, aorta and SW1088 glioblastoma cells. Barely detectable expression was found in 20 RNA extracted from right atrium, right ventricle, kidney cortex, and kidney medulla. Only complete protection of the RP3 probe was seen. The lack of partial protection argues against the cDNA cgbL23.1 (a variant cDNA described in Example 7) representing a major transcript, at least in these RNA samples.

Example 9

25 Polyclonal antisera was raised to *E. coli*-produced fragments of the human cGB-PDE.

A portion of the human cGB-PDE cDNA (nucleotides 1668-2612 of 30 SEQ ID NO: 22, amino acids 515-819 of SEQ ID NO: 23) was amplified by PCR and inserted into the *E. coli* expression vector pGEX2T (Pharmacia) as a *Bam*H/*Eco*RI fragment. The pGEX2T plasmid carries an ampicillin resistance gene, an *E. coli* lac I^a gene and a portion of the *Schistosoma japonicum* glutathione-S-

WO 94/28144

PCT/US94/06066

-32-

transferase (GST) gene. DNA inserted in the plasmid can be expressed as a fusion protein with GST and can then be cleaved from the GST portion of the protein with thrombin. The resulting plasmid, designated cgbPE3, was transformed into *E. coli* strain LE392 (Stratagene). Transformed cells were grown at 37°C to an OD600 of 5 0.6. IPTG (isopropylthioalactopyranoside) was added to 0.1mM and the cells were grown at 37°C for an additional 2 hours. The cells were collected by centrifugation and lysed by sonication. Cell debris was removed by centrifugation and the supernatant was fractionated by SDS-PAGE. The gel was stained with cold 0.4M KCl and the GST-cgb fusion protein band was excised and electroeluted. The PDE 10 portion of the protein was separated from the GST portion by digestion with thrombin. The digest was fractionated by SDS-PAGE, the PDE protein was electroeluted and injected subcutaneously into a rabbit. The resultant antisera recognizes both the bovine cGB-PDE fragment that was utilized as antigen and the full length human cGB-PDE protein expressed in yeast (see Example 8).

15

Example 10

Polynucleotides encoding various cGB-PDE analogs and cGB-PDE fragments were generated by standard methods.

A. cGB-PDE Analogs

20 All known cGMP-binding PDEs contain two internally homologous tandem repeats within their putative cGMP-binding domains. In the bovine cGB-PDE of the invention, the repeats span at least residues 228-311 (repeat A) and 410-500 (repeat B) of SEQ ID NO: 10. Site-directed mutagenesis of an aspartic acid that is conserved in repeats A and B of all known cGMP-binding PDEs was used to create 25 analogs of cGB-PDE having either Asp-289 replaced with Ala (D289A) or Asp-478 replaced with Ala (D478A). Recombinant wild type (WT) bovine and mutant bovine cGB-PDEs were expressed in COS-7 cells. cGB-PDE purified from bovine lung (native cGB-PDE) and WT cGB-PDE displayed identical cGMP-binding kinetics with a K_d of approximately 2 μ M and a curvilinear dissociation profile ($t_{1/2} = 1.3$ hours at 4°C). This curvilinearity may have been due to the presence of distinct high affinity 30 (slow) and low affinity (fast) sites of cGMP binding. The D289A mutant had significantly decreased affinity for cGMP ($K_d > 20\mu\text{M}$) and a single rate of cGMP-

WO 94/28144

PCT/US94/06066

-33-

association ($t_{1/2} = 0.5$ hours), that was similar to that calculated for the fast site of WT and native cGB-PDE. This suggested the loss of a slow cGMP-binding site in repeat **A** of this mutant. Conversely, the D478A mutant showed higher affinity for cGMP (K_d of approximately $0.5 \mu\text{M}$) and a single cGMP-dissociation rate ($t_{1/2} = 2.8$ hours) that was similar to the calculated rate of the slow site of WT and native cGB-PDE. This suggested the loss of a fast site when repeat **B** was modified. These results indicate that dimeric cGB-PDE possesses two homologous but kinetically distinct cGMP-binding sites, with the conserved aspartic acid being critical for interaction with cGMP at each site. See, Colbran *et al.*, *FASEB J.*, 8: Abstract 2149 (May 15, 1994).

10 **B. Amino-Terminal Truncated cGB-PDE Polypeptides**

15 A truncated human cGB-PDE polypeptide including amino acids 516-875 of SEQ ID NO: 23 was expressed in yeast. A cDNA insert extending from the NcoI site at nucleotide 1555 of SEQ ID NO: 22 through the XhoI site at the 3' end of SEQ ID NO: 22 was inserted into the ADH2 yeast expression vector YEpc-PADH2d [Price *et al.*, *Meth. Enzymol.*, 185: 308-318 (1990)] that had been digested with NcoI and SalI to generate plasmid YEpc-PADH2d HcGB. The plasmid was transformed into spheroplasts of the yeast strain yBJ2-54 (prcl-407 prb1-1122 pep4-3 leu2 trpl ura3-52 Δ pde1::URA3, HIS3 Δ pde2::TRP1 cir $^+$). The endogenous PDE genes are deleted in this strain. Cells were grown in SC-leu media with 2% glucose to 10^7 cells/ml, collected by filtration and grown 24 hours in YEP media containing 3% glycerol. Cells were pelleted by centrifugation and stored frozen. Cells were disrupted with glass beads and the cell homogenate was assayed for phosphodiesterase activity essentially as described in Prpic *et al.*, *Anal. Biochem.*, 208: 155-160 (1993).

20 The truncated human cGB-PDE polypeptide exhibited phosphodiesterase activity.

25

C. Carboxy-Terminal Truncated cGB-PDE Polypeptides

Two different plasmids encoding carboxy-terminal truncated human cGB-PDE polypeptides were constructed.

30 Plasmid pBJ6-84Hin contains a cDNA encoding amino acids 1-494 of SEQ ID NO: 23 inserted into the NcoI and SalI sites of vector YEpc-PADH2d. The cDNA insert extends from the NcoI site at nucleotide position 10 of SEQ ID NO: 22

WO 94/28144

PCT/US94/06066

-34-

through the HindIII site at nucleotide position 1494 of SEQ ID NO: 22 followed by a linker and the SalI site of YEpc-PADH2d.

5 Plasmid pBJ6-84Ban contains a cDNA encoding amino acids 1-549 of SEQ ID NO: 23 inserted into the NcoI and SalI sites of vector YEpc-PADH2d. The cDNA insert extends from the NcoI site at nucleotide position 10 of SEQ ID NO: 22 through the BanI site at nucleotide position 1657 of SEQ ID NO: 22 followed by a linker and the SalI site of YEpc-PADH2d.

The truncated cGB-PDE polypeptides are useful for screening for modulators of cGB-PDE activity.

10

Example 11

Monoclonal antibodies reactive with human cGB-PDE were generated.

15 Yeast yBJ2-54 containing the plasmid YEpcADH2 HcGB (Example 10B) were fermented in a New Brunswick Scientific 10 liter Microferm. The cGB-PDE cDNA insert in plasmid YEpcADH2 HcGB extends from the NcoI site at nucleotide 12 of SEQ ID NO: 22 to the XhoI site at the 3' end of SEQ ID NO: 22. An inoculum of 4×10^9 cells was added to 8 liters of media containing SC-leu, 5% glucose, trace metals, and trace vitamins. Fermentation was maintained at 26°C, agitated at 600 rpm with the standard microbial impeller, and aerated with compressed air at 10 volumes per minute. When glucose decreased to 0.3% at 24 hours post-inoculation the culture was infused with 2 liters of 5X YEP media containing 15% glycerol. At 66 hours post-inoculation the yeast from the ferment was harvested by centrifugation at 4,000 x g for 30 minutes at 4°C. Total yield of biomass from this fermentation approached 350 g wet weight.

20 Human cGB-PDE enzyme was purified from the yeast cell pellet. Assays for PDE activity using 1 mM cGMP as substrate was employed to follow the chromatography of the enzyme. All chromatographic manipulations were performed at 4°C.

25 Yeast (29g wet weight) were resuspended in 70ml of buffer A (25mM Tris pH 8.0, 0.25mM DTT, 5mM MgCl₂, 10μM ZnSO₄, 1mM benzamidine) and 30 lysed by passing through a microfluidizer at 22-24,000 psi. The lysate was centrifuged at 10,000 x g for 30 minutes and the supernatant was applied to a 2.6 x

WO 94/28144

PCT/US94/06066

-35-

28 cm column containing Pharmacia Fast Flow Q anion exchange resin equilibrated with buffer B containing 20mM BisTris-propane pH 6.8, 0.25mM DTT, 1mM MgCl₂, and 10μM ZnSO₄. The column was washed with 5 column volumes of buffer B containing 0.125M NaCl and then developed with a linear gradient from 0.125 to 5 1.0M NaCl. Fractions containing the enzyme were pooled and applied directly to a 5 x 20 cm column of ceramic hydroxyapatite (BioRad) equilibrated in buffer C containing 20mM BisTris-propane pH 6.8, 0.25mM DTT, 0.25MKCl, 1mM MgCl₂, and 10μM ZnSO₄. The column was washed with 5 column volumes of buffer C and eluted with a linear gradient from 0 to 250mM potassium phosphate in buffer C. The 10 pooled enzyme was concentrated 8-fold by ultrafiltration (YM30 membrane, Amicon). The concentrated enzyme was chromatographed on a 2.6 x 90 cm column of Pharmacia Sephadryl S300 (Piscataway, NJ) equilibrated in 25mM BisTris-propane pH 6.8, 0.25mM DTT, 0.25M NaCl, 1mM MgCl₂, and 20μM ZnSO₄. Approximately 4 mg of protein was obtained. The recombinant human cGB-PDE enzyme accounted 15 for approximately 90% of protein obtained as judged by SDS polyacrylamide gel electrophoresis followed by Coomassie blue staining.

The purified protein was used as an antigen to raise monoclonal antibodies. Each of 19 week old Balb/c mice (Charles River Biotechnical Services, Inc., Wilmington, Mass.) was immunized sub-cutaneously with 50 ug purified human 20 cGB-PDE enzyme in a 200 ul emulsion consisting of 50% Freund's complete adjuvant (Sigma Chemical Co.). Subsequent boosts on day 20 and day 43 were administered in incomplete Freund's adjuvant. A pre-fusion boost was done on day 86 using 50 ug enzyme in PBS. The fusion was performed on day 90.

The spleen from mouse #1817 was removed steriley and placed in 25 10ml serum free RPMI 1640. A single-cell suspension was formed and filtered through sterile 70-mesh Nitex cell strainer (Becton Dickinson, Parsippany, New Jersey), and washed twice by centrifuging at 200 g for 5 minutes and resuspending the pellet in 20 ml serum free RPMI. Thymocytes taken from 3 naive Balb/c mice were prepared in a similar manner.

30 NS-1 myeloma cells, kept in log phase in RPMI with 11% Fetalclone (FBS) (Hyclone Laboratories, Inc., Logan, Utah) for three days prior to fusion, were centrifuged at 200 g for 5 minutes, and the pellet was washed twice as described in

WO 94/28144

PCT/US94/06066

-36-

the foregoing paragraph. After washing, each cell suspension was brought to a final volume of 10 ml in serum free RPMI, and 20 μ l was diluted 1:50 in 1 ml serum free RPMI. 20 μ l of each dilution was removed, mixed with 20 μ l 0.4% trypan blue stain in 0.85% saline (Gibco), loaded onto a hemocytometer (Baxter Healthcare Corp., Deerfield, Illinois) and counted.

Two $\times 10^8$ spleen cells were combined with 4.0 $\times 10^7$ NS-1 cells, centrifuged and the supernatant was aspirated. The cell pellet was dislodged by tapping the tube and 2 ml of 37°C PEG 1500 (50% in 75 mM Hepes, pH 8.0) (Boehringer Mannheim) was added with stirring over the course of 1 minute, followed by adding 14 ml of serum free RPMI over 7 minutes. An additional 16 ml RPMI was added and the cells were centrifuged at 200 g for 10 minutes. After discarding the supernatant, the pellet was resuspended in 200 ml RPMI containing 15% FBS, 100 μ M sodium hypoxanthine, 0.4 μ M aminopterin, 16 μ M thymidine (HAT) (Gibco), 25 units/ml IL-6 (Boehringer Mannheim) and 1.5 $\times 10^6$ thymocytes/ml. The suspension was first placed in a T225 flask (Corning, United Kingdom) at 37°C for two hours before being dispensed into ten 96-well flat bottom tissue culture plates (Corning, United Kingdom) at 200 μ l/well. Cells in plates were fed on days 3, 4, 5 post fusion day by aspirating approximately 100 μ l from each well with an 20 G needle (Becton Dickinson), and adding 100 μ l/well plating medium described above except containing 10 units/ml IL-6 and lacking thymocytes.

The fusion was screened initially by ELISA. Immulon 4 plates (Dynatech) were coated at 4°C overnight with purified recombinant human cGB-PDE enzyme (100ng/well in 50mM carbonate buffer pH9.6). The plates were washed 3X with PBS containing 0.05 % Tween 20 (PBST). The supernatants from the individual hybridoma wells were added to the enzyme coated wells (50 μ l/well). After incubation at 37°C for 30 minutes, and washing as above, 50 μ l of horseradish peroxidase conjugated goat anti-mouse IgG(fc) (Jackson ImmunoResearch, West Grove, Pennsylvania) diluted 1:3500 in PBST was added. Plates were incubated as above, washed 4X with PBST and 100 μ l substrate consisting of 1 mg/ml o-phenylene diamine (Sigma) and 0.1 μ l/ml 30% H₂O₂ in 100 mM citrate, pH 4.5, was added. The color reaction was stopped in 5 minutes with the addition of 50 μ l of 15% H₂SO₄. A₄₉₀ was read on a plate reader (Dynatech).

WO 94/28144

PCT/US94/06066

-37-

5 Wells C5G, E4D, F1G, F9H, F11G, J4A, and J5D were picked and renamed 102A, 102B, 102C, 102D, 102E, 102F, and 102G respectively, cloned two or three times, successively, by doubling dilution in RPMI, 15% FBS, 100 μ M sodium hypoxanthine, 16 μ M thymidine, and 10 units/ml IL-6. Wells of clone plates were scored visually after 4 days and the number of colonies in the least dense wells were recorded. Selected wells of the each cloning were tested by ELISA.

10 The monoclonal antibodies produced by above hybridomas were isotyped in an ELISA assay. Results showed that monoclonal antibodies 102A to 102E were IgG1, 102F was IgG2b and 102G was IgG2a.

15 All seven monoclonal antibodies reacted with human cGS-PDE as determined by Western analysis.

Example 12

20 Developing modulators of the biological activities of specific PDEs requires differentiating PDE isozymes present in a particular assay preparation. The classical enzymological approach of isolating PDEs from natural tissue sources and studying each new isozyme is hampered by the limits of purification techniques and the inability to definitively assess whether complete resolution of a isozyme has been achieved. Another approach has been to identify assay conditions which might favor the contribution of one isozyme and minimize the contribution of others in a preparation. Still another approach has been the separation of PDEs by immunological means. Each of the foregoing approaches for differentiating PDE isozymes is time consuming and technically difficult. As a result many attempts to develop selective PDE modulators have been performed with preparations containing more than one isozyme. Moreover, PDE preparations from natural tissue sources are susceptible to limited proteolysis and may contain mixtures of active proteolytic products that have different kinetic, regulatory and physiological properties than the full length PDEs.

25 Recombinant cGB-PDE polypeptide products of the invention greatly facilitate the development of new and specific cGB-PDE modulators. The use of human recombinant enzymes for screening for modulators has many inherent advantages. The need for purification of an isozyme can be avoided by expressing

WO 94/28144

PCT/US94/06066

-38-

it recombinantly in a host cell that lacks endogenous phosphodiesterase activity (e.g., yeast strain YKS45 deposited as ATCC 74225). Screening compounds against human protein avoids complications that often arise from screening against non-human protein where a compound optimized on a non-human protein may fail to be specific for or react with the human protein. For example, a single amino acid difference between the human and rodent 5HT_{1B} serotonin receptors accounts for the difference in binding of a compound to the receptors. [See Oskenberg *et al.*, *Nature*, 360: 161-163 (1992)]. Once a compound that modulates the activity of the cGB-PDE is discovered, its selectivity can be evaluated by comparing its activity on the cGB-PDE to its activity on other PDE isozymes. Thus, the combination of the recombinant cGB-PDE products of the invention with other recombinant PDE products in a series of independent assays provides a system for developing selective modulators of cGB-PDE. Selective modulators may include, for example, antibodies and other proteins or peptides which specifically bind to the cGB-PDE or cGB-PDE nucleic acid, oligonucleotides which specifically bind to the cGB-PDE (see Patent Cooperation Treaty International Publication No. WO93/05182 published March 18, 1993 which describes methods for selecting oligonucleotides which selectively bind to target biomolecules) or cGB-PDE nucleic acid (e.g., antisense oligonucleotides) and other non-peptide natural or synthetic compounds which specifically bind to the cGB-PDE or cGB-PDE nucleic acid. Mutant forms of the cGB-PDE which alter the enzymatic activity of the cGB-PDE or its localization in a cell are also contemplated. Crystallization of recombinant cGB-PDE alone and bound to a modulator, analysis of atomic structure by X-ray crystallography, and computer modelling of those structures are methods useful for designing and optimizing non-peptide selective modulators. See, for example, Erickson *et al.*, *Ann. Rep. Med. Chem.*, 27: 271-289 (1992) for a general review of structure-based drug design.

Targets for the development of selective modulators include, for example: (1) the regions of the cGB-PDE which contact other proteins and/or localize the cGB-PDE within a cell, (2) the regions of the cGB-PDE which bind substrate, (3) the allosteric cGMP-binding site(s) of cGB-PDE, (4) the metal-binding regions of the cGB-PDE, (5) the phosphorylation site(s) of cGB-PDE and (6) the regions of the cGB-PDE which are involved in dimerization of cGB-PDE subunits.

WO 94/28144

PCT/US94/06066

-39-

While the present invention has been described in terms of specific embodiments, it is understood that variations and modifications will occur to those skilled in the art. Accordingly, only such limitations as appear in the appended claims should be placed on the invention.

WO 94/28144

PCT/US94/06066

-40-

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: The Board of Regents of the University of Washington

(ii) TITLE OF INVENTION: Cyclic GMP-Binding, Cyclic GMP-Specific Phosphodiesterase Materials and Methods

(iii) NUMBER OF SEQUENCES: 23

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
(B) STREET: 6300 Sears Tower, 233 S. Wacker Drive
(C) CITY: Chicago
(D) STATE: Illinois
(E) COUNTRY: USA
(F) ZIP: 60606

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 08/068,051
(B) FILING DATE: 27-MAY-1993

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Noland, Greta E.
(B) REGISTRATION NUMBER: 35,302
(C) REFERENCE/DOCKET NUMBER: 32083

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (312) 474-6300
(B) TELEFAX: (312) 474-0448
(C) TELEX: 25-3856

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

WO 94/28144

PCT/US94/06066

-41-

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Arg	Glu	Xaa	Asp	Ala	Asn	Arg	Ile	Asn	Tyr	Met	Tyr	Ala	Gln	Tyr	Val
1															15
5															
20															
Lys	Asn	Thr	Met												

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Gln	Ser	Leu	Ala	Ala	Ala	Val	Val	Pro
1								
5								

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Phe	Asp	Asn	Asp	Glu	Gly	Glu	Gln
1							
5							

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 23 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

TTYGAYAAYG AYGARGGNGA RCA

23

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 23 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (iv) ANTI-SENSE: YES

WO 94/28144

PCT/US94/06066

-43-

(ix) FEATURE:

(A) NAME/KEY: CDS
(B) LOCATION: 99..2723

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9

GGGAGGGTCT CGACCGAGT TCTGCTCTC GGAGGGAGGG ACCCCAGCTG GAGTGGAAA	60
CCAGCACCAAG CTGACCGCAG AGACACGCCG CGCTGATC ATG GAG AGG GCC GGC Met Glu Arg Ala Gly	113
1 5	
CCC GGC TGC CGC GCG GCC GCA ACA GCA ATG GGA CCA GGA CTC GGT CGA Pro Gly Cys Arg Ala Ala Ala Thr Ala Met Gly Pro Gly Leu Gly Arg	161
10 15 20	
AGC GTG GCT GGA CGA TCA CTG GGA CTT TAC CTT CTC TAC TTT GTT AGG Ser Val Ala Gly Arg Ser Leu Gly Leu Tyr Leu Leu Tyr Phe Val Arg	209
25 30 35	
AAA GGC ACC AGA GAA ATG GTC AAC GCA TGG TTT GCT GAG AGA GTT CAC Lys Gly Thr Arg Glu Met Val Asn Ala Trp Phe Ala Glu Arg Val His	257
40 45 50	
ACC ATT CCT GTG TGC AAG GAA GGA ATC AAG GGC CAC ACG GAA TCC TGC Thr Ile Pro Val Cys Lys Glu Gly Ile Lys Gly His Thr Glu Ser Cys	305
55 60 65	
TCT TGC CCC TTG CAG CCA AGT CCC CGT GCA GAG AGC AGT GTC CCT GGA Ser Cys Pro Leu Gln Pro Ser Pro Arg Ala Glu Ser Ser Val Pro Gly	353
70 75 80 85	
ACA CCA ACC AGG AAG ATC TCT GCC TCT GAA TTC GAT CGG CCG CTT AGA Thr Pro Thr Arg Lys Ile Ser Ala Ser Glu Phe Asp Arg Pro Leu Arg	401
90 95 100	
CCC ATC GTT ATC AAG GAT TCT GAG GGA ACT GTG AGC TTC CTC TCT GAC Pro Ile Val Ile Lys Asp Ser Glu Gly Thr Val Ser Phe Leu Ser Asp	449
105 110 115	
TCA GAC AAG AAG GAA CAG ATG CCT CTA ACC TCC CCA CGG TTT GAT AAT Ser Asp Lys Lys Glu Gln Met Pro Leu Thr Ser Pro Arg Phe Asp Asn	497
120 125 130	
GAT GAA GGG GAC CAG TGC TCG AGA CTC TTG GAA TTA GTG AAA GAT ATT Asp Glu Gly Asp Gln Cys Ser Arg Leu Leu Glu Leu Val Lys Asp Ile	545
135 140 145	
TCT AGT CAC TTG GAT GTC ACA GCC TTA TGT CAC AAA ATT TTC TTG CAC Ser Ser His Leu Asp Val Thr Ala Leu Cys His Lys Ile Phe Leu His	593
150 155 160 165	
ATC CAT GGA CTC ATC TCC GCC GAC CGC TAC TCC TTA TTC CTC GTC TGT Ile His Gly Leu Ile Ser Ala Asp Arg Tyr Ser Leu Phe Leu Val Cys	641
170 175 180	
GAG GAC AGC TCC AAC GAC AAG TTT CTT ATC AGC CGC CTC TTT GAT GTT Glu Asp Ser Ser Asn Asp Lys Phe Leu Ile Ser Arg Leu Phe Asp Val	689
185 190 195	
GCA GAA GGT TCA ACA CTG GAA GAA GCT TCA AAC AAC TGC ATC CGC TTA Ala Glu Gly Ser Thr Leu Glu Ala Ser Asn Asn Cys Ile Arg Leu	737
200 205 210	

WO 94/28144

PCT/US94/06066

-44-

GAG TGG AAC AAA GGC ATC GTG GGA CAC GTG GCC GCT TTT GGC GAG CCC Glu Trp Asn Lys Gly Ile Val Gly His Val Ala Ala Phe Gly Glu Pro 215 220 225	785
TTG AAC ATC AAA GAC GCC TAT GAG GAT CCT CGA TTC AAT GCA GAA GTT Leu Asn Ile Lys Asp Ala Tyr Glu Asp Pro Arg Phe Asn Ala Glu Val 230 235 240 245	833
GAC CAA ATT ACA GGC TAC AAG ACA CAA AGT ATT CTT TGT ATG CCA ATT Asp Gln Ile Thr Gly Tyr Lys Thr Gln Ser Ile Leu Cys Met Pro Ile 250 255 260	881
AAG AAT CAT AGG GAA GAG GTT GTT GGT GTA GCC CAG GCC ATC AAC AAG Lys Asn His Arg Glu Glu Val Val Gly Val Ala Gln Ala Ile Asn Lys 265 270 275	929
AAA TCA GGA AAT GGT GGG ACA TTC ACT GAA AAA GAC GAA AAG GAC TTT Lys Ser Gly Asn Gly Gly Thr Phe Thr Glu Lys Asp Glu Lys Asp Phe 280 285 290	977
GCT GCT TAC TTG GCA TTT TGT GGA ATT GTT CTT CAT AAT GCT CAA CTC Ala Ala Tyr Leu Ala Phe Cys Gly Ile Val Leu His Asn Ala Gln Leu 295 300 305	1025
TAT GAG ACT TCA CTG CTG GAG AAC AAG AGA AAT CAG GTG CTG CTT GAC Tyr Glu Thr Ser Leu Leu Glu Asn Lys Arg Asn Gln Val Leu Leu Asp 310 315 320 325	1073
CTT GCT AGC TTA ATT TTT GAA GAA CAA CAA TCA TTA GAA GTA ATT CTA Leu Ala Ser Leu Ile Phe Glu Glu Gln Gln Ser Leu Glu Val Ile Leu 330 335 340	1121
AGG AAA ATA GCT GCC ACT ATT ATC TCT CCC ATG CAG GTG CAG AAA TGC Arg Lys Ile Ala Ala Thr Ile Ile Ser Pro Met Gln Val Gln Lys Cys 345 350 355	1169
ACC ATT TTC ATA GTG GAT GAA GAT TGC TCC GAT TCT TTT TCT AGT GTG Thr Ile Phe Ile Val Asp Glu Asp Cys Ser Asp Ser Phe Ser Ser Val 360 365 370	1217
TTT CAC ATG GAG TGT GAG GAA TTA GAA AAA TCG TCA GAT ACT TTA ACA Phe His Met Glu Cys Glu Leu Glu Lys Ser Ser Asp Thr Leu Thr 375 380 385	1265
CGG GAA CGT GAT GCA ACC AGA ATC AAT TAC ATG TAT GCT CAG TAT GTC Arg Glu Arg Asp Ala Thr Arg Ile Asn Tyr Met Tyr Ala Gln Tyr Val 390 395 400 405	1313
AAA AAT ACC ATG GAA CCA CTT AAT ATC CCA GAC GTC AGT AAG GAC AAA Lys Asn Thr Met Glu Pro Leu Asn Ile Pro Asp Val Ser Lys Asp Lys 410 415 420	1361
AGA TTT CCC TGG ACA AAT GAA AAC ATG GGA AAT ATA AAC CAG CAG TGC Arg Phe Pro Trp Thr Asn Glu Asn Met Gly Asn Ile Asn Gln Gln Cys 425 430 435	1409
ATT AGA AGT TTG CTT TGT ACA CCT ATA AAA AAT GGA AAG AAG AAC AAA Ile Arg Ser Leu Leu Cys Thr Pro Ile Lys Asn Gly Lys Lys Asn Lys 440 445 450	1457
GTG ATA GGG GTT TGC CAA CTT GTT AAT AAG ATG GAG GAA ACC ACT GGC Val Ile Gly Val Cys Gln Leu Val Asn Lys Met Glu Glu Thr Thr Gly 455 460 465	1505

WO 94/28144

PCT/US94/06066

-45-

AAA GTT AAG GCT TTC AAC CGC AAC GAT GAA CAG TTT CTG GAA GCT TTC Lys Val Lys Ala Phe Asn Arg Asn Asp Glu Gln Phe Leu Glu Ala Phe 470 475 480 485	1553
GTC ATC TTT TGT GGC TTG GGG ATC CAG AAC ACA CAG ATG TAC GAA GCA Val Ile Phe Cys Gly Leu Gly Ile Gln Asn Thr Gln Met Tyr Glu Ala 490 495 500	1601
GTG GAG AGA GCC ATG GCC AAG CAA ATG GTC ACG TTA GAG GTT CTG TCT Val Glu Arg Ala Met Ala Lys Gln Met Val Thr Leu Glu Val Leu Ser 505 510 515	1649
TAT CAT GCT TCA GCT GCA GAG GAA GAA ACC AGA GAG CTG CAG TCC TTA Tyr His Ala Ser Ala Ala Glu Glu Glu Thr Arg Glu Leu Gln Ser Leu 520 525 530	1697
GCG GCT GCT GTG GTA CCA TCT GCC CAG ACC CTT AAA ATC ACT GAC TTC Ala Ala Ala Val Val Pro Ser Ala Gln Thr Leu Lys Ile Thr Asp Phe 535 540 545	1745
AGC TTC AGC GAC TTT GAG CTG TCT GAC CTG GAA ACA GCA CTG TGC ACA Ser Phe Ser Asp Phe Glu Leu Ser Asp Leu Glu Thr Ala Leu Cys Thr 550 555 560 565	1793
ATC CGG ATG TTC ACT GAC CTC AAC CTT GTG CAG AAC TTC CAG ATG AAA Ile Arg Met Phe Thr Asp Leu Asn Leu Val Gln Asn Phe Gln Met Lys 570 575 580	1841
CAT GAG GTC CTT TGC AAG TGG ATT TTA AGT GTG AAG AAG AAC TAT CGG His Glu Val Leu Cys Lys Trp Ile Leu Ser Val Lys Lys Asn Tyr Arg 585 590 595	1889
AAG AAC GTC GCC TAT CAT AAT TGG AGA CAT GCC TTT AAT ACA GCT CAG Lys Asn Val Ala Tyr His Asn Trp Arg His Ala Phe Asn Thr Ala Gln 600 605 610	1937
TGC ATG TTT GCG GCA CTA AAA GCA GCC AAA ATT CAG AAG AGG CTG ACG Cys Met Phe Ala Ala Leu Lys Ala Gly Lys Ile Gln Lys Arg Leu Thr 615 620 625	1985
GAC CTG GAG ATA CTT GCA CTG CTG ATT GCT GCC TTA AGC CAT GAT CTG Asp Leu Glu Ile Leu Ala Leu Leu Ile Ala Ala Leu Ser His Asp Leu 630 635 640 645	2033
GAT CAC CGT GGT GTC AAT AAC TCA TAC ATA CAG CGA AGT GAA CAC CCA Asp His Arg Gly Val Asn Asn Ser Tyr Ile Gln Arg Ser Glu His Pro 650 655 660	2081
CTT GCT CAG CTC TAC TGC CAT TCA ATC ATG GAG CAT CAT CAT TTT GAT Leu Ala Gln Leu Tyr Cys His Ser Ile Met Glu His His His Phe Asp 665 670 675	2129
CAG TGC CTG ATG ATC CTT AAT AGT CCT GGC AAT CAG ATT CTC AGT GGC Gln Cys Leu Met Ile Leu Asn Ser Pro Gly Asn Gln Ile Leu Ser Gly 680 685 690	2177
CTC TCC ATT GAA GAG TAT AAG ACC ACC CTG AAG ATC ATC AAG CAA GCT Leu Ser Ile Glu Glu Tyr Lys Thr Thr Leu Lys Ile Ile Lys Gln Ala 695 700 705	2225
ATT TTA GCC ACA GAC CTA GCA CTG TAC ATA AAG AGA CGA GGA GAA TTT Ile Leu Ala Thr Asp Leu Ala Leu Tyr Ile Lys Arg Arg Gly Glu Phe 710 715 720 725	2273
TTT GAA CTT ATA ATG AAA AAT CAA TTC AAT TTG GAA GAT CCT CAT CAA Phe Glu Leu Ile Met Lys Asn Gln Phe Asn Leu Glu Asp Pro His Gln 730 735 740	2321

WO 94/28144

PCT/US94/06066

-46-

AAG GAG TTG TTT TTA GCG ATG CTG ATG ACA GCT TGT GAT CTT TCT GCA Lys Glu Leu Phe Leu Ala Met Leu Met Thr Ala Cys Asp Leu Ser Ala 745 750 755	2369
ATT ACA AAA CCC TGG CCT ATT CAA CAA CGG ATA GCA GAA CTT GTT GCC Ile Thr Lys Pro Trp Pro Ile Gln Gln Arg Ile Ala Glu Leu Val Ala 760 765 770	2417
ACT GAA TTT TTT GAC CAA GGA GAT AGA GAG AGG AAA GAA CTC AAC ATA Thr Glu Phe Phe Asp Gln Gly Asp Arg Glu Arg Lys Glu Leu Asn Ile 775 780 785	2465
GAG CCC GCT GAT CTA ATG AAC CGG GAG AAG AAA AAC AAA ATC CCA AGT Glu Pro Ala Asp Leu Met Asn Arg Glu Lys Lys Asn Lys Ile Pro Ser 790 795 800 805	2513
ATG CAA GTT GGA TTC ATA GAT GCC ATC TGC TTG CAA CTG TAT GAG GCC Met Gln Val Gly Phe Ile Asp Ala Ile Cys Leu Gln Leu Tyr Glu Ala 810 815 820	2561
TTG ACC CAT GTG TCG GAG GAC TGT TTC CCT TTG CTG GAC GGC TGC AGA Leu Thr His Val Ser Glu Asp Cys Phe Pro Leu Leu Asp Gly Cys Arg 825 830 835	2609
AAG AAC AGG CAG AAA TGG CAG GCT CTT GCA GAA CAG CAG GAG AAG ACA Lys Asn Arg Gln Lys Trp Gln Ala Leu Ala Glu Gln Gln Glu Lys Thr 840 845 850	2657
CTG ATC AAT GGT GAA AGC AGC CAG ACC AAC CGA CAG CAA CGG AAT TCC Leu Ile Asn Gly Glu Ser Ser Gln Thr Asn Arg Gln Gln Arg Asn Ser 855 860 865	2705
GTT GCT GTC GGG ACA GTG TAGCCAGGTG TATCAGATGA GTGAGTGTGT Val Ala Val Gly Thr Val 870 875	2753
GCTCAGCTCA GTCCTCTGCA ACACCATGAA GCTAGGCATT CCAGCTTAAT TCCTGCAGTT GACTTTAAAA AACTGGCATA AAGCACTAGT CAGCATCTAG TTCTAGCTTG ACCAGTGAAG AGTAGAACAC CACCACAGTC AGGGTGCAGA GCAGTTGGCA GTCTCCTTTC CAACCCAGAC TGGTGAATTAA AAAGAAGAGC AGTCGTCGTT TATATCTCTG TCTTTTCCTA AGGGGGGTGT GGAATCTCTA AGAGGAGAGA GAGATCTGGA CCACAGGTCC AATGCCCTCT GTCCCTCTCAG CTGCTTCCCC CACTGTGCTG TGACCTCTCA ATCTGAGAAA CGTGTAAAGGA AGGTTTCAGC GAATTCCCTT TAAAATGTGT CAGACAGTAG CTTCTTGGGC CGGGTTGTTC CCGCAGCTCC CCATCTGTTC TTGTCATC TTGGCTGAAA GAGGCTTGC TGTACCTGCC ACACTCTCCT GGATCCCTGT CCAGTAGCTG ATCAAAAAAA AGGATGTGAA ATTCTCGTGT GACTTTTTAG AAAAGGAAAG TGACCCCCGAG GATCGGTGTG GATTCACTAG TTGTCACAG ATGATCTGTT TAGTTCTAG AATTTTCCAA GATGATACAC TCCTCCCTAG TCTAGGGTC AGACCCCTGTA TGGTGGCTGT GACCCCTTGAG GAACTCTCT CTTTGCATGA CATTACCCAT AGAACTGTTC TTGTCCTTAAAT ACACAGCTCA TATGCAGCTT GCAGGAAACA CTTTAAAAAC ACAACTATCA CCTATGTTAT TCTGATTACA GAAGTTATCC CTACTCACTG TAAACATAAA CAAAGCCCC CRAACTTCCTA ATAGTTGTGT GTGGTGAGAA ACTGCAAGTT TTCACTCTCCA GAGATAGCTA TAGGTAATAA GTGGGATGTT TCTGAAACTT TTTAAAAATAA TCTTTTACAT ATATGTTAAC	2813 2873 2933 2993 3053 3113 3173 3233 3293 3353 3413 3473 3533 3593 3653 3713

WO 94/28144

PCT/US94/06066

-47-

TGTTTTCTTA	TGAGCACTAT	GGTTTGT	TTTTTTTTTG	TGCTCTGCTT	TGACTTGCCC	3773
TTTCACTCA	ATTATCTTGG	CAGTTTTCT	AAATGACTTG	CACAGACTTC	TCCTGTACTT	3833
CATGGCTGTG	CAGTGTCCA	TGCTGTGAAG	GCACCATCGT	GTATTAAATC	AGTCCCTGG	3893
TCACACATAG	GTGAGCTGGT	TGGAAATT	TACCATTA	AAACCAC	CCCACATTGA	3953
TGCTTTCTAA	TCTGGCACAG	GATGCTCTT	TTTTTCCCCT	TTTCTCTGT	TTAATTATTG	4013
GAAATGGGAT	CTGTGGGATC	CTCGTTCCCT	GGCACCTAGC	TGCTCTCAAC	GTGGCCTGTG	4073
GCCAGCAGCA	TTGGCTAGAC	CTGGGGCTT	GTTGGGAACG	GAGACCCCTCT	GCCCTGCC	4133
TGGCCTGCTG	ACAAGGACCT	GCATTTGCT	GAGCTCCAG	TGACCCCTGGT	GTTAATTGT	4193
TAACCATTGA	AAAAAAATCAA	ACTATAGTTT	ATTTACAATG	TTGTGTTAAT	TTGGGTGTA	4253
CAGCAAAGTG	ACTCACTGGT	CAACTACATT	AAAACACTG	GGCATACTCT	CTCCCTCTCC	4313
TTGTGTACCT	GGTTGGTATT	TCCAGAAACC	ATGCTCTGT	CTGTCCTGTA	GTTTGGAAG	4373
CGCTTTCTCT	TTGAAGACTG	CCTCTCTCC	TGTGTCTGCC	CTACATGGAC	TAGTCGTTT	4433
ATTGTCTTAC	ATGGCTTGC	TTCCATGTTC	CTCTCAACTT	T		4474

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 875 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Met	Glu	Arg	Ala	Gly	Pro	Gly	Cys	Arg	Ala	Ala	Ala	Thr	Ala	Met	Gly
1					5				10					15	
Pro	Gly	Leu	Gly	Arg	Ser	Val	Ala	Gly	Arg	Ser	Leu	Gly	Leu	Tyr	Leu
		20				25					30				
Leu	Tyr	Phe	Val	Arg	Lys	Gly	Thr	Arg	Glu	Met	Val	Asn	Ala	Trp	Phe
		35				40					45				
Ala	Glu	Arg	Val	His	Thr	Ile	Pro	Val	Cys	Lys	Glu	Gly	Ile	Lys	Gly
	50				55					60					
His	Thr	Glu	Ser	Cys	Ser	Cys	Pro	Leu	Gln	Pro	Ser	Pro	Arg	Ala	Glu
	65				70				75				80		
Ser	Ser	Val	Pro	Gly	Thr	Pro	Thr	Arg	Lys	Ile	Ser	Ala	Ser	Glu	Phe
		85					90					95			
Asp	Arg	Pro	Leu	Arg	Pro	Ile	Val	Ile	Lys	Asp	Ser	Glu	Gly	Thr	Val
		100				105						110			
Ser	Phe	Leu	Ser	Asp	Ser	Asp	Lys	Lys	Glu	Gln	Met	Pro	Leu	Thr	Ser
	115					120					125				
Pro	Arg	Phe	Asp	Asn	Asp	Glu	Gly	Asp	Gln	Cys	Ser	Arg	Leu	Leu	Glu
	130					135					140				
Leu	Val	Lys	Asp	Ile	Ser	Ser	His	Leu	Asp	Val	Thr	Ala	Leu	Cys	His
	145					150					155			160	

WO 94/28144

PCT/US94/06066

-48-

Lys Ile Phe Leu His Ile His Gly Leu Ile Ser Ala Asp Arg Tyr Ser
 165 170 175
 Leu Phe Leu Val Cys Glu Asp Ser Ser Asn Asp Lys Phe Leu Ile Ser
 180 185 190
 Arg Leu Phe Asp Val Ala Glu Gly Ser Thr Leu Glu Glu Ala Ser Asn
 195 200 205
 Asn Cys Ile Arg Leu Glu Trp Asn Lys Gly Ile Val Gly His Val Ala
 210 215 220
 Ala Phe Gly Glu Pro Leu Asn Ile Lys Asp Ala Tyr Glu Asp Pro Arg
 225 230 235 240
 Phe Asn Ala Glu Val Asp Gln Ile Thr Gly Tyr Lys Thr Gln Ser Ile
 245 250 255
 Leu Cys Met Pro Ile Lys Asn His Arg Glu Glu Val Val Gly Val Ala
 260 265 270
 Gln Ala Ile Asn Lys Lys Ser Gly Asn Gly Gly Thr Phe Thr Glu Lys
 275 280 285
 Asp Glu Lys Asp Phe Ala Ala Tyr Leu Ala Phe Cys Gly Ile Val Leu
 290 295 300
 His Asn Ala Gln Leu Tyr Glu Thr Ser Leu Leu Glu Asn Lys Arg Asn
 305 310 315 320
 Gln Val Leu Leu Asp Leu Ala Ser Leu Ile Phe Glu Glu Gln Gln Ser
 325 330 335
 Leu Glu Val Ile Leu Arg Lys Ile Ala Ala Thr Ile Ile Ser Pro Met
 340 345 350
 Gln Val Gln Lys Cys Thr Ile Phe Ile Val Asp Glu Asp Cys Ser Asp
 355 360 365
 Ser Phe Ser Ser Val Phe His Met Glu Cys Glu Glu Leu Glu Lys Ser
 370 375 380
 Ser Asp Thr Leu Thr Arg Glu Arg Asp Ala Thr Arg Ile Asn Tyr Met
 385 390 395 400
 Tyr Ala Gln Tyr Val Lys Asn Thr Met Glu Pro Leu Asn Ile Pro Asp
 405 410 415
 Val Ser Lys Asp Lys Arg Phe Pro Trp Thr Asn Glu Asn Met Gly Asn
 420 425 430
 Ile Asn Gln Gln Cys Ile Arg Ser Leu Leu Cys Thr Pro Ile Lys Asn
 435 440 445
 Gly Lys Lys Asn Lys Val Ile Gly Val Cys Gln Leu Val Asn Lys Met
 450 455 460
 Glu Glu Thr Thr Gly Lys Val Lys Ala Phe Asn Arg Asn Asp Glu Gln
 465 470 475 480
 Phe Leu Glu Ala Phe Val Ile Phe Cys Gly Leu Gly Ile Gln Asn Thr
 485 490 495
 Gln Met Tyr Glu Ala Val Glu Arg Ala Met Ala Lys Gln Met Val Thr
 500 505 510

WO 94/28144

PCT/US94/06066

-49-

Leu Glu Val Leu Ser Tyr His Ala Ser Ala Ala Glu Glu Glu Thr Arg
 515 520 525
 Glu Leu Gln Ser Leu Ala Ala Ala Val Val Pro Ser Ala Gln Thr Leu
 530 535 540
 Lys Ile Thr Asp Phe Ser Phe Ser Asp Phe Glu Leu Ser Asp Leu Glu
 545 550 555 560
 Thr Ala Leu Cys Thr Ile Arg Met Phe Thr Asp Leu Asn Leu Val Gln
 565 570 575
 Asn Phe Gln Met Lys His Glu Val Leu Cys Lys Trp Ile Leu Ser Val
 580 585 590
 Lys Lys Asn Tyr Arg Lys Asn Val Ala Tyr His Asn Trp Arg His Ala
 595 600 605
 Phe Asn Thr Ala Gln Cys Met Phe Ala Ala Leu Lys Ala Gly Lys Ile
 610 615 620
 Gln Lys Arg Leu Thr Asp Leu Glu Ile Leu Ala Leu Leu Ile Ala Ala
 625 630 635 640
 Leu Ser His Asp Leu Asp His Arg Gly Val Asn Asn Ser Tyr Ile Gln
 645 650 655
 Arg Ser Glu His Pro Leu Ala Gln Leu Tyr Cys His Ser Ile Met Glu
 660 665 670
 His His His Phe Asp Gln Cys Leu Met Ile Leu Asn Ser Pro Gly Asn
 675 680 685
 Gln Ile Leu Ser Gly Leu Ser Ile Glu Glu Tyr Lys Thr Thr Leu Lys
 690 695 700
 Ile Ile Lys Gln Ala Ile Leu Ala Thr Asp Leu Ala Leu Tyr Ile Lys
 705 710 715 720
 Arg Arg Gly Glu Phe Phe Glu Leu Ile Met Lys Asn Gln Phe Asn Leu
 725 730 735
 Glu Asp Pro His Gln Lys Glu Leu Phe Leu Ala Met Leu Met Thr Ala
 740 745 750
 Cys Asp Leu Ser Ala Ile Thr Lys Pro Trp Pro Ile Gln Gln Arg Ile
 755 760 765
 Ala Glu Leu Val Ala Thr Glu Phe Phe Asp Gln Gly Asp Arg Glu Arg
 770 775 780
 Lys Glu Leu Asn Ile Glu Pro Ala Asp Leu Met Asn Arg Glu Lys Lys
 785 790 795 800
 Asn Lys Ile Pro Ser Met Gln Val Gly Phe Ile Asp Ala Ile Cys Leu
 805 810 815
 Gln Leu Tyr Glu Ala Leu Thr His Val Ser Glu Asp Cys Phe Pro Leu
 820 825 830
 Leu Asp Gly Cys Arg Lys Asn Arg Gln Lys Trp Gln Ala Leu Ala Glu
 835 840 845
 Gln Gln Glu Lys Thr Leu Ile Asn Gly Glu Ser Ser Gln Thr Asn Arg
 850 855 860

WO 94/28144

PCT/US94/06066

-50-

Gln Gln Arg Asn Ser Val Ala Val Gly Thr Val
 865 870 875

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 2060 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GGGGCCGCGC TCCGGCCGCT TTGTCGAAAG CCGGCCCCGAC TGGAGCAGGA CGAAGGGGGA	60
GGGTCTCGAG CCCGAGTCCT GTTCTTCTGA GGGACGGACC CCAGCTGGGG TGAAAAGCA	120
GTACCCAGAGA GCCTCCGAGG CGCCGCGGTGC CAACCATGGA GCGGGCCGGC CCCAGCTTCG	180
GGCAGCAGCG ACAGCAGCAG CAGCCCCAGC AGCAGAAGCA GCAGCAGAGG GATCAGGACT	240
CGGTCGAAGC ATGGCTGGAC GATCACTGGG ACTTTACCTT CTCATACTTT GTTAGAAAAG	300
CCACCCAGAGA AATGGTCAAT GCATGGTTTG CTGAGAGAGT TCACACCATC CCTGTGTGCA	360
AGGAAGGTAT CAGAGGCCAC ACCGAATCTT GCTCTTGTC CTTGCAGCAG AGTCCTCGTG	420
CAGATAACAG TGTCCCTGGA ACACCAACCA GGAAAATCTC TGCCCTCTGAA TTTGACCGGC	480
CTCTTAGACC CATTGTTGTC AAGGATTCTG AGGGAACTGT GAGCTTCCTC TCTGACTCAG	540
AAAAGAAGGA ACAGATGCCCT CTAACCCCTC CAAGGTTTGA TCATGATGAA GGGGACCAGT	600
GCTCAAGACT CTTGGAATTAA GTGAAGGATA TTTCTAGTCA TTTGGATGTC ACAGCCTTAT	660
GTCACAAAAT TTTCTTGCTAT ATCCATGGAC TGATATCTGC TGACCGCTAT TCCCTGTTCC	720
TTGTCGTGAA AGACAGCTCC AATGACAAGT TTCTTATCAG CCGCCTCTTT GATGTTGCTG	780
AAGGTTCAAC ACTGGAAGAA GTTTCAAATA ACTGTATCCG CTTAGAATGG AACAAAGGCA	840
TTGTGGGACA TGTGGCAGCG CTTGGTGAGC CCTTGAACAT CAAAGATGCA TATGAGGATC	900
CTCGGTTCAA TGCAGAAAGTT GACCAAATTAA CAGGCTACAA GACACAAAGC ATTCTTTGTA	960
TGCCAATTAA GAATCATAGG GAAGAGGTG TTGGTGTAGC CCAGGCCATC AACAAAGAAAT	1020
CAGGAAACGG TGGGACATTT ACTGAAAAG ATGAAAAGGA CTTTGTGCT TATTGGCAT	1080
TTTGTGGTAT TGTTCTTCAT AATGCTCAGC TCTATGAGAC TTCACTGCTG GAGAACAAAGA	1140
GAATCAGGT GCTGCTTGAC CTTGCTAGTT TAATTTTGAA AGAACAAACAA TCATTAGAAG	1200
TAATTTGAA GAAAATAGCT GCCACTATTAA TCTCTTTCAT GCAAGTGCAG AAATGCACCA	1260
TTTCATAGT CGATGAAGAT TGCTCCGATT CTTTTCTAG TGTGTTTCAC ATGGAGTGTG	1320
AGGAATTAGA AAAATCATCT GATACATTAA CAAGGGAACA TGATGCAAAC AAAATCAATT	1380
ACATGTATGC TCACTATGTC AAAAATACTA TGGAACCACT TTATATCCCA GATGTCAGTA	1440
AGGATAAAAG ATTTCCCTGG ACAACTGAAA ATACAGGAAA TGTAAACCAAG CAGTGCATTA	1500

WO 94/28144

PCT/US94/06066

-51-

GAAGTTGCT TTGTACACCT ATAAAAATG GAAAGAAGAA TAAAGTTATA GGGGTTGCC	1560
AACTTGTAA TAAGATGGAG GAGAATACTG GCAAGGTTAA GCCTTCAAC CGAAATGACG	1620
AACAGTTCT GGAAGCTTT GTCATCTTT GTGGCTTGGG GATCCAGAAC ACCCAGATGT	1680
ATGAAGCAGT GGAGAGAGCC ATGGCCAAGC AAATGGTCAC ATTGGAGGTT CTGTCGTATC	1740
ATGCTTCAGC AGCAGAGGAA GAAACAAGAG AGCTACAGTC GTTACGGCT GCTGTGGTGC	1800
CATCTGCCA GACCCTTAAA ATTACTGACT TTAGCTTCAG TGACTTTGAG CTGTCGTGATC	1860
TGGAAACAGC ACTGTGTACA ATTGGATGT TTACTGACCT CAACCTGTG CAGAACTTCC	1920
AGATGAAACA TGAGGTTCTT TGCAGATGGA TTTTAAGTGT TAAGAAGAAT TATCGGAAGA	1980
ATGTTGCCTA TCATAATTGG AGACATGCCT TTAATACAGC TCAGTGCATG TTTGCTGCTC	2040
TAAAAGCAGG CAAAATTCAG	2060

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1982 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

ACAAAATTTT CTTGCATATC CATGGACTGA TATCTGCTGA CCGCTATTCC CTGTTCTTG	60
TCTGTGAAGA CAGCTCCAAT GACAAGTTTC TTATCAGCCG CCTCTTTGAT GTTGTGAAG	120
GTTCAACACT CGAAGAAGTT TCAAATAACT GTATCCGCTT AGAATGGAAC AAAGGCATTG	180
TGGGACATGT GCCAGCGCTT GGTGAGCCCT TGAACATCAA AGATGCATAT GAGGATCCTC	240
GGTTCAATGC AGAAGTTGAC CAAATTACAG GCTACAAGAC ACAAAAGCATT CTTTGTATGC	300
CAATTAAGAA TCATAGGGAA GAGGTGTTG GTGTAGCCCA GGCCATCAAC AAGAAATCAG	360
GAAACGGTGG GACATTTACT GAAAAAGATG AAAAGGACTT TGCTGCTTAT TTGGCATTTT	420
GTGGTATTGT TCTTCATAAT GCTCAGCTCT ATGAGACTTC ACTGCTGGAG AACAAAGAGAA	480
ATCAGGTGCT GCTTGACCTT GCTAGTTAA TTTTGAAGA ACAACAATCA TTAGAAGTAA	540
TTTTGAAGAA AATAGCTGCC ACTATTATCT CTTTCATGCA AGTGCAGAAA TGCACCATT	600
TCATAGTGG A TCAAGATTGC TCCGATTCTT TTTCTAGTGT GTTTCACATG GAGTGTGAGG	660
AATTAGAAAA ATCATCTGAT ACATTAACAA GGGAACATGA TGCACCAAAA ATCAATTACA	720
TGTATGCTCA GTATGTCAAA AATACTATGG AACCACTTAA TATCCCAGAT GTCAGTAAGG	780
ATAAAAGATT TCCCTGGACA ACTGAAAATA CAGGAAATGT AAACCAGCAG TGCATTAGAA	840
GTGGCTTTG TACACCTATA AAAAATGGAA AGAAGAATAA AGTTATAGGG GTTGCCAAAC	900
TTGTTAATAA GATGGAGGAG AATACTGGCA AGGTTAAGCC TTTCAACCGA AATGACGAAC	960
AGTTTCTGGA AGCTTTGTC ATCTTTGTC GCTTGGGGAT CCAGAACACG CAGATGTATG	1020

WO 94/28144

PCT/US94/06066

-52-

AAGCAGTGGA GAGAGCCATG GCCAAGCAAA TGGTCACATT GGAGGTTCTG TCGTATCATG	1080
CTTCAGCAGC AGAGGAAGAA ACAAGAGAGC TACAGTCGTT AGCGGCTGCT GTGGTGCCAT	1140
CTGCCCAGAC CCTTAAAATT ACTGACTTTA GCTTCAGTGA CTTTGAGCTG TCTGATCTGG	1200
AAACAGCACT GTGTACAATT CGGATGTTA CTGACCTCAA CCTTGTGCAG AACTTCCAGA	1260
TGAAACATGA GGTTCTTGC AGATGGATT TAAGTGTAA GAAGAATTAT CGGAAGAATG	1320
TTGCCTATCA TAATTGGAGA CATGCCTTA ATACAGCTCA GTGCATGTT GCTGCTCTAA	1380
AAGCAGGCAA AATTCAAAAC AAGCTGACTG ACCTGGAGAT ACCTGCATTG CTGATTGCTG	1440
CACTAAGGCCA CGATTTGGAT CACCGTGGTG TGAATAACTC TTACATACAG CGAAGTGAAC	1500
ATCCACTTGC CCAGCTTTAC TGCCATTCAA TCATGGAACA CCATCATTG GACCAGTGCC	1560
TGATGATTCT TAATAGTCCA GGCAATCAGA TTCTCAGTGG CCTCTCCATT GAAGAATATA	1620
AGACCACGTT GAAAATAATC AAGCAAGCTA TTTTAGCTAC AGACCTAGCA CTGTACATTA	1680
AGAGGCGAGG AGAATTTTT GAACCTATAA GAAAAATCA ATTCAATTG GAAGATCCTC	1740
ATCAAAAGGA GTTGTGTTTG GCAATGCTGA TGACAGCTTG TGATCTTCT GCAATTACAA	1800
AACCCTGGCC TATTCAACAA CGGATAGCAG AACTTGTAGC AACTGAATTT TTTGATCAAG	1860
GAGACAGAGA GAGAAAAGAA CTCAACATAG AACCCACTGA TCTAATGAAC AGGGAGAAGA	1920
AAAACAAAAT CCCAAGTATG CAAGTTGGGT TCATAGATGC CATCTGCTTG CAACTGTATG	1980
AG	1982

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

GCCACCAAGAG AAATGGTC 18

(2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

ACAATGGGTC TAAAGAGGC 18

WO 94/28144

PCT/US94/06066

-53-

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

TCAGTGCATG TTTGCTGC

18

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

TACAAACATG TTCATCAG

18

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1107 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

GAGACATGCC TTTAATACAG CTCAGTGCAT GTTGCTGCT CTAAAAGCAG GCAAAATTCA	60
GAACAAGCTG ACTGACCTGG AGATACTTGC ATTGCTGATT GCTGCACTAA GCCACGATTT	120
GGATCACCGT GGTGTGAATA ACTCTTACAT ACAGCGAACT GAACATCCAC TTGCCCAGCT	180
TTACTGCCAT TCAATCATGG AACACCCTCA TTTTGACCAAG TGCCTGATGA TTCTTAATAG	240
TCCAGGCAAT CAGATTCTCA GTGGCCTCTC CATTGAAGAA TATAAGACCA CGTTGAAAAT	300
AATCAAGCAA GCTATTTAG CTACAGACCT AGCACTGTAC ATTAAGAGGC GAGGAGAATT	360
TTTGAACTT ATAAGAAAAA ATCAATTCAA TTTGGAAGAT CCTCATCAAA AGGAGTTGTT	420
TTTGGCAATG CTGATGACAG CTTGTGATCT TTCTGCAATT ACAAAACCCCT GGCCTATTCA	480
ACAACGGATA GCAGAACTTG TAGCAACTGA ATTTTTGAT CAAGGAGACA GAGAGAGAAA	540
AGAACTCAAC ATAGAACCCA CTGATCTAAT GAACAGGGAG AAGAAAAACA AAATCCCAAG	600
TATGCAAGTT GGGTTCATAG ATGCCATCTG CTTGCAACTG TATGAGGCC CGTACCCACGT	660

WO 94/28144

PCT/US94/06066

-54-

GTCAGAGGAC TGTTCCCTT TGCTAGATGG CTGCAGAAAG AACAGGCAGA AATGGCAGGC	720
CCTTGCAGAA CAGCAGGAGA AGATGCTGAT TAATGGGGAA AGCGGCCAGG CCAAGCGGAA	780
CTGAGTGGCC TATTCATGC AGAGTTGAAG TTTACAGAGA TGGTGTGTTC TGCAATATGC	840
CTAGTTCTT ACACACTGTC TGTATAGTGT CTGTATTGGA TATATACTTT GCCACTGCTG	900
TATTTTTATT TTTGCACAAAC TTTTGAGAGT ATAGCATGAA TGTTTTAGA GGACTATTAC	960
ATATTTTTTG TATATTGTT TTATGCTACT GAACTGAAAG GATCAACAAAC ATCCACTGTT	1020
ACGCACATTGA TAAAAGCATT GTTGTGATA TTTCGTGTAC TGCAAAGTGT ATGCAGTATT	1080
CTTGCACGTGA GGTTTTTTTG CTTGGGG	1107

(2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

TTTGAAGAT CCTCATCA 18

(2) INFORMATION FOR SEQ ID NO:19:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 28 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

ATGTCTCGAG TCAGTTCCGC TTGGCCTG 28

(2) INFORMATION FOR SEQ ID NO:20:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 30 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

TACAGAATTC TGACCATGGA GCGGGCCGGC 30

WO 94/28144

PCT/US94/06066

-55-

(2) INFORMATION FOR SEQ ID NO:21:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

CATTCTAACG CGGATACAG

18

(2) INFORMATION FOR SEQ ID NO:22:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 2645 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 12..2636

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

GAATTCTGAC C ATG GAG CGG GCC GGC CCC AGC TTC GGG CAG CAG CGA CAG	50
Met Glu Arg Ala Gly Pro Ser Phe Gly Gln Gln Arg Gln	
1 5 10	

CAG CAG CAG CCC CAG CAG AAG CAG CAG CAG AGG GAT CAG GAC TCG	98
Gln Gln Pro Gln Gln Gln Lys Gln Gln Gln Arg Asp Gln Asp Ser	
15 20 25	

GTC GAA GCA TGG CTG GAC GAT CAC TGG GAC TTT ACC TTC TCA TAC TTT	146
Val Glu Ala Trp Leu Asp Asp His Trp Asp Phe Thr Phe Ser Tyr Phe	
30 35 40 45	

GTT AGA AAA GCC ACC AGA GAA ATG GTC AAT GCA TGG TTT GCT GAG AGA	194
Val Arg Lys Ala Thr Arg Glu Met Val Asn Ala Trp Phe Ala Glu Arg	
50 55 60	

GTT CAC ACC ATC CCT GTG TGC AAG GAA GGT ATC AGA GGC CAC ACC GAA	242
Val His Thr Ile Pro Val Cys Lys Glu Gly Ile Arg Gly His Thr Glu	
65 70 75	

TCT TGC TCT TGT CCC TTG CAG CAG AGT CCT CGT GCA GAT AAC AGT GTC	290
Ser Cys Ser Cys Pro Leu Gln Gln Ser Pro Arg Ala Asp Asn Ser Val	
80 85 90	

CCT GGA ACA CCA ACC AGG AAA ATC TCT GCC TCT GAA TTT GAC CGG CCT	338
Pro Gly Thr Pro Thr Arg Lys Ile Ser Ala Ser Glu Phe Asp Arg Pro	
95 100 105	

CTT AGA CCC ATT GTT GTC AAG GAT TCT GAG GGA ACT GTG AGC TTC CTC	386
Leu Arg Pro Ile Val Val Lys Asp Ser Glu Gly Thr Val Ser Phe Leu	
110 115 120 125	

WO 94/28144

PCT/US94/06066

-56-

TCT GAC TCA GAA AAG AAG GAA CAG ATG CCT CTA ACC CCT CCA AGG TTT Ser Asp Ser Glu Lys Lys Glu Gln Met Pro Leu Thr Pro Pro Arg Phe 130 135 140	434
GAT CAT GAT GAA GGG GAC CAG TGC TCA AGA CTC TTG GAA TTA GTG AAG Asp His Asp Glu Gly Asp Gln Cys Ser Arg Leu Leu Glu Leu Val Lys 145 150 155	482
GAT ATT TCT AGT CAT TTG GAT GTC ACA GCC TTA TGT CAC AAA ATT TTC Asp Ile Ser Ser His Leu Asp Val Thr Ala Leu Cys His Lys Ile Phe 160 165 170	530
TTG CAT ATC CAT GGA CTG ATA TCT GCT GAC CGC TAT TCC CTG TTC CTT Leu His Ile His Gly Leu Ile Ser Ala Asp Arg Tyr Ser Leu Phe Leu 175 180 185	578
GTC TGT GAA GAC AGC TCC AAT GAC AAG TTT CTT ATC AGC CGC CTC TTT Val Cys Glu Asp Ser Ser Asn Asp Lys Phe Leu Ile Ser Arg Leu Phe 190 195 200 205	626
GAT GTT GCT GAA GGT TCA ACA CTG GAA GAA GTT TCA AAT AAC TGT ATC Asp Val Ala Glu Gly Ser Thr Leu Glu Glu Val Ser Asn Asn Cys Ile 210 215 220	674
CGC TTA GAA TGG AAC AAA GGC ATT GTG GGA CAT GTG GCA GCG CTT GGT Arg Leu Glu Trp Asn Lys Gly Ile Val Gly His Val Ala Ala Leu Gly 225 230 235	722
GAG CCC TTG AAC ATC AAA GAT GCA TAT GAG GAT CCT CGG TTC AAT GCA Glu Pro Leu Asn Ile Lys Asp Ala Tyr Glu Asp Pro Arg Phe Asn Ala 240 245 250	770
GAA GTT GAC CAA ATT ACA GGC TAC AAG ACA CAA AGC ATT CTT TGT ATG Glu Val Asp Gln Ile Thr Gly Tyr Lys Thr Gln Ser Ile Leu Cys Met 255 260 265	818
CCA ATT AAG AAT CAT AGG GAA GAG GTT GTT GGT GTA GCC CAG GCC ATC Pro Ile Lys Asn His Arg Glu Glu Val Val Gly Val Ala Gln Ala Ile 270 275 280 285	866
AAC AAG AAA TCA GGA AAC GGT GGG ACA TTT ACT GAA AAA GAT GAA AAG Asn Lys Lys Ser Gly Asn Gly Gly Thr Phe Thr Glu Lys Asp Glu Lys 290 295 300	914
GAC TTT GCT TAT TTG GCA TTT TGT GGT ATT GTT CTT CAT AAT GCT Asp Phe Ala Ala Tyr Leu Ala Phe Cys Gly Ile Val Leu His Asn Ala 305 310 315	962
CAG CTC TAT GAG ACT TCA CTG CTG GAG AAC AAG AGA AAT CAG GTG CTG Gln Leu Tyr Glu Thr Ser Leu Leu Glu Asn Lys Arg Asn Gln Val Leu 320 325 330	1010
CTT GAC CTT GCT AGT TTA ATT TTT GAA GAA CAA CAA TCA TTA GAA GTA Leu Asp Leu Ala Ser Leu Ile Phe Glu Glu Gln Gln Ser Leu Glu Val 335 340 345	1058
ATT TTG AAG AAA ATA GCT GCC ACT ATT ATC TCT TTC ATG CAA GTG CAG Ile Leu Lys Lys Ile Ala Ala Thr Ile Ile Ser Phe Met Gln Val Gln 350 355 360 365	1106
AAA TGC ACC ATT TTC ATA GTG GAT GAA GAT TGC TCC GAT TCT TTT TCT Lys Cys Thr Ile Phe Ile Val Asp Glu Asp Cys Ser Asp Ser Phe Ser 370 375 380	1154
ACT GTG TTT CAC ATG GAG TGT GAG GAA TTA GAA AAA TCA TCT GAT ACA Ser Val Phe His Met Glu Cys Glu Leu Glu Lys Ser Ser Asp Thr 385 390 395	1202

WO 94/28144

PCT/US94/06066

-57-

TTA ACA AGG GAA CAT GAT GCA AAC AAA ATC AAT TAC ATG TAT GCT CAG Leu Thr Arg Glu His Asp Ala Asn Lys Ile Asn Tyr Met Tyr Ala Gln 400 405 410	1250
TAT GTC AAA AAT ACT ATG GAA CCA CTT AAT ATC CCA GAT GTC AGT AAG Tyr Val Lys Asn Thr Met Glu Pro Leu Asn Ile Pro Asp Val Ser Lys 415 420 425	1298
GAT AAA AGA TTT CCC TGG ACA ACT GAA AAT ACA GGA AAT GTA AAC CAG Asp Lys Arg Phe Pro Trp Thr Thr Glu Asn Thr Gly Asn Val Asn Gln 430 435 440 445	1346
CAG TGC ATT AGA AGT TTG CTT TGT ACA CCT ATA AAA AAT GGA AAG AAG Gln Cys Ile Arg Ser Leu Leu Cys Thr Pro Ile Lys Asn Gly Lys Lys 450 455 460	1394
AAT AAA GTT ATA GGG GTT TGC CAA CTT GTT AAT AAG ATG GAG GAG AAT Asn Lys Val Ile Gly Val Cys Gln Leu Val Asn Lys Met Glu Glu Asn 465 470 475	1442
ACT GGC AAG GTT AAG CCT TTC AAC CGA AAT GAC GAA CAG TTT CTG GAA Thr Gly Lys Val Lys Pro Phe Asn Arg Asn Asp Glu Gln Phe Leu Glu 480 485 490	1490
GCT TTT GTC ATC TTT TGT GGC TTG GGG ATC CAG AAC ACG CAG ATG TAT Ala Phe Val Ile Phe Cys Gly Leu Gly Ile Gln Asn Thr Gln Met Tyr 495 500 505	1538
GAA GCA GTG GAG AGA GCC ATG GCC AAG CAA ATG GTC ACA TTG GAG GTT Glu Ala Val Glu Arg Ala Met Ala Lys Gln Met Val Thr Leu Glu Val 510 515 520 525	1586
CTG TCG TAT CAT GCT TCA GCA GCA GAG GAA ACA ACA GAG CTA CAG Leu Ser Tyr His Ala Ser Ala Ala Glu Glu Thr Arg Glu Leu Gln 530 535 540	1634
TCG TTA GCG GCT GCT GTG CCA TCT GCC CAG ACC CTT AAA ATT ACT Ser Leu Ala Ala Val Val Pro Ser Ala Gln Thr Leu Lys Ile Thr 545 550 555	1682
GAC TTT AGC TTC AGT GAC TTT GAG CTG TCT GAT CTG GAA ACA GCA CTG Asp Phe Ser Phe Ser Asp Phe Glu Leu Ser Asp Leu Glu Thr Ala Leu 560 565 570	1730
TGT ACA ATT CGG ATG TTT ACT GAC CTC AAC CTT GTG CAG AAC TTC CAG Cys Thr Ile Arg Met Phe Thr Asp Leu Asn Leu Val Gln Asn Phe Gln 575 580 585	1778
ATG AAA CAT GAG GTT CTT TGC AGA TGG ATT TTA AGT GTT AAG AAG AAT Met Lys His Glu Val Leu Cys Arg Trp Ile Leu Ser Val Lys Lys Asn 590 595 600 605	1826
TAT CGG AAG AAT GTT GCC TAT CAT AAT TGG AGA CAT GCC TTT AAT ACA Tyr Arg Lys Asn Val Ala Tyr His Asn Trp Arg His Ala Phe Asn Thr 610 615 620	1874
GCT CAG TGC ATG TTT GCT CTA AAA GCA GGC AAA ATT CAG AAC AAG Ala Gln Cys Met Phe Ala Ala Leu Lys Ala Gly Lys Ile Gln Asn Lys 625 630 635	1922
CTG ACT GAC CTG GAG ATA CTT GCA TTG CTG ATT GCT GCA CTA AGC CAC Leu Thr Asp Leu Glu Ile Leu Ala Leu Ile Ala Leu Ser His 640 645 650	1970
GAT TTG GAT CAC CGT GGT GTG AAT AAC TCT TAC ATA CAG CGA AGT GAA Asp Leu Asp His Arg Gly Val Asn Asn Ser Tyr Ile Gln Arg Ser Glu 655 660 665	2018

WO 94/28144

PCT/US94/06066

-58-

CAT CCA CTT GCC CAG CTT TAC TGC CAT TCA ATC ATG GAA CAC CAT CAT His Pro Leu Ala Gln Leu Tyr Cys His Ser Ile Met Glu His His His 670 675 680 685	2066
TTT GAC CAG TGC CTG ATG ATT CTT AAT AGT CCA GGC AAT CAG ATT CTC Phe Asp Gln Cys Leu Met Ile Leu Asn Ser Pro Gly Asn Gln Ile Leu 690 695 700	2114
AGT GGC CTC TCC ATT CAA GAA TAT AAG ACC ACG TTG AAA ATA ATC AAG Ser Gly Leu Ser Ile Glu Glu Tyr Lys Thr Thr Leu Lys Ile Ile Lys 705 710 715	2162
CAA GCT ATT TTA GCT ACA GAC CTA GCA CTG TAC ATT AAG AGG CGA GGA Gln Ala Ile Leu Ala Thr Asp Leu Ala Leu Tyr Ile Lys Arg Arg Gly 720 725 730	2210
GAA TTT TTT GAA CTT ATA AGA AAA AAT CAA TTC AAT TTG GAA GAT CCT Glu Phe Phe Glu Leu Ile Arg Lys Asn Gln Phe Asn Leu Glu Asp Pro 735 740 745	2258
CAT CAA AAG GAG TTG TTT TTG GCA ATG CTG ATG ACA GCT TGT GAT CTT His Gln Lys Glu Leu Phe Leu Ala Met Leu Met Thr Ala Cys Asp Leu 750 755 760 765	2306
TCT GCA ATT ACA AAA CCC TGG CCT ATT CAA CAA CGG ATA GCA GAA CTT Ser Ala Ile Thr Lys Pro Trp Pro Ile Gln Gln Arg Ile Ala Glu Leu 770 775 780	2354
GTA GCA ACT GAA TTT TTT GAT CAA GGA GAC AGA GAG AGA AAA GAA CTC Val Ala Thr Glu Phe Phe Asp Gln Gly Asp Arg Glu Arg Lys Glu Leu 785 790 795	2402
AAC ATA GAA CCC ACT GAT CTA ATG AAC AGC GAG AAG AAA AAC AAA ATC Asn Ile Glu Pro Thr Asp Leu Met Asn Arg Glu Lys Lys Asn Lys Ile 800 805 810	2450
CCA AGT ATG CAA GTT GGG TTC ATA GAT GCC ATC TGC TTG CAA CTG TAT Pro Ser Met Gln Val Gly Phe Ile Asp Ala Ile Cys Leu Gln Leu Tyr 815 820 825	2498
GAG GCC CTG ACC CAC GTG TCA GAG GAC TGT TTC CCT TTG CTA GAT GGC Glu Ala Leu Thr His Val Ser Glu Asp Cys Phe Pro Leu Leu Asp Gly 830 835 840 845	2546
TGC AGA AAG AAC AGG CAG AAA TGG CAG GCC CTT GCA GAA CAG CAG GAG Cys Arg Lys Asn Arg Gln Lys Trp Gln Ala Leu Ala Glu Gln Glu 850 855 860	2594
AAG ATG CTG ATT AAT GGG GAA AGC GGC CAG GCC AAG CGG AAC Lys Met Leu Ile Asn Gly Ser Gly Gln Ala Lys Arg Asn 865 870 875	2636
TGACTCGAG	2645
(2) INFORMATION FOR SEQ ID NO:23:	
(i) SEQUENCE CHARACTERISTICS:	
(A) LENGTH: 875 amino acids	
(B) TYPE: amino acid	
(D) TOPOLOGY: linear	
(ii) MOLECULE TYPE: protein	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:	
Met Glu Arg Ala Gly Pro Ser Phe Gly Gln Gln Arg Gln Gln Gln Gln 1 5 10 15	

WO 94/28144

PCT/US94/06066

-59-

Pro Gln Gln Gln Lys Gln Gln Gln Arg Asp Gln Asp Ser Val Glu Ala
 20 25 30

Trp Leu Asp Asp His Trp Asp Phe Thr Phe Ser Tyr Phe Val Arg Lys
 35 40 45

Ala Thr Arg Glu Met Val Asn Ala Trp Phe Ala Glu Arg Val His Thr
 50 55 60

Ile Pro Val Cys Lys Glu Gly Ile Arg Gly His Thr Glu Ser Cys Ser
 65 70 75 80

Cys Pro Leu Gln Gln Ser Pro Arg Ala Asp Asn Ser Val Pro Gly Thr
 85 90 95

Pro Thr Arg Lys Ile Ser Ala Ser Glu Phe Asp Arg Pro Leu Arg Pro
 100 105 110

Ile Val Val Lys Asp Ser Glu Gly Thr Val Ser Phe Leu Ser Asp Ser
 115 120 125

Glu Lys Lys Glu Gln Met Pro Leu Thr Pro Pro Arg Phe Asp His Asp
 130 135 140

Glu Gly Asp Gln Cys Ser Arg Leu Leu Glu Leu Val Lys Asp Ile Ser
 145 150 155 160

Ser His Leu Asp Val Thr Ala Leu Cys His Lys Ile Phe Leu His Ile
 165 170 175

His Gly Leu Ile Ser Ala Asp Arg Tyr Ser Leu Phe Leu Val Cys Glu
 180 185 190

Asp Ser Ser Asn Asp Lys Phe Leu Ile Ser Arg Leu Phe Asp Val Ala
 195 200 205

Glu Gly Ser Thr Leu Glu Glu Val Ser Asn Asn Cys Ile Arg Leu Glu
 210 215 220

Trp Asn Lys Gly Ile Val Gly His Val Ala Ala Leu Gly Glu Pro Leu
 225 230 235 240

Asn Ile Lys Asp Ala Tyr Glu Asp Pro Arg Phe Asn Ala Glu Val Asp
 245 250 255

Gln Ile Thr Gly Tyr Lys Thr Gln Ser Ile Leu Cys Met Pro Ile Lys
 260 265 270

Asn His Arg Glu Glu Val Val Gly Val Ala Gln Ala Ile Asn Lys Lys
 275 280 285

Ser Gly Asn Gly Gly Thr Phe Thr Glu Lys Asp Glu Lys Asp Phe Ala
 290 295 300

Ala Tyr Leu Ala Phe Cys Gly Ile Val Leu His Asn Ala Gln Leu Tyr
 305 310 315 320

Glu Thr Ser Leu Leu Glu Asn Lys Arg Asn Gln Val Leu Leu Asp Leu
 325 330 335

Ala Ser Leu Ile Phe Glu Glu Gln Gln Ser Leu Glu Val Ile Leu Lys
 340 345 350

Lys Ile Ala Ala Thr Ile Ile Ser Phe Met Gln Val Gln Lys Cys Thr
 355 360 365

WO 94/28144

PCT/US94/06066

-60-

Ile Phe Ile Val Asp Glu Asp Cys Ser Asp Ser Phe Ser Ser Val Phe
 370 375 380
 His Met Glu Cys Glu Glu Leu Glu Lys Ser Ser Asp Thr Leu Thr Arg
 385 390 395 400
 Glu His Asp Ala Asn Lys Ile Asn Tyr Met Tyr Ala Gln Tyr Val Lys
 405 410 415
 Asn Thr Met Glu Pro Leu Asn Ile Pro Asp Val Ser Lys Asp Lys Arg
 420 425 430
 Phe Pro Trp Thr Thr Glu Asn Thr Gly Asn Val Asn Gln Gln Cys Ile
 435 440 445
 Arg Ser Leu Leu Cys Thr Pro Ile Lys Asn Gly Lys Lys Asn Lys Val
 450 455 460

 Ile Gly Val Cys Gln Leu Val Asn Lys Met Glu Glu Asn Thr Gly Lys
 465 470 475 480
 Val Lys Pro Phe Asn Arg Asn Asp Glu Gln Phe Leu Glu Ala Phe Val
 485 490 495
 Ile Phe Cys Gly Leu Gly Ile Gln Asn Thr Gln Met Tyr Glu Ala Val
 500 505 510
 Glu Arg Ala Met Ala Lys Gln Met Val Thr Leu Glu Val Leu Ser Tyr
 515 520 525
 His Ala Ser Ala Ala Glu Glu Glu Thr Arg Glu Leu Gln Ser Leu Ala
 530 535 540
 Ala Ala Val Val Pro Ser Ala Gln Thr Leu Lys Ile Thr Asp Phe Ser
 545 550 555 560
 Phe Ser Asp Phe Glu Leu Ser Asp Leu Glu Thr Ala Leu Cys Thr Ile
 565 570 575
 Arg Met Phe Thr Asp Leu Asn Leu Val Gln Asn Phe Gln Met Lys His
 580 585 590
 Glu Val Leu Cys Arg Trp Ile Leu Ser Val Lys Lys Asn Tyr Arg Lys
 595 600 605
 Asn Val Ala Tyr His Asn Trp Arg His Ala Phe Asn Thr Ala Gln Cys
 610 615 620
 Met Phe Ala Ala Leu Lys Ala Gly Lys Ile Gln Asn Lys Leu Thr Asp
 625 630 635 640
 Leu Glu Ile Leu Ala Leu Ile Ala Ala Leu Ser His Asp Leu Asp
 645 650 655
 His Arg Gly Val Asn Asn Ser Tyr Ile Gln Arg Ser Glu His Pro Leu
 660 665 670
 Ala Gln Leu Tyr Cys His Ser Ile Met Glu His His His Phe Asp Gln
 675 680 685
 Cys Leu Met Ile Leu Asn Ser Pro Gly Asn Gln Ile Leu Ser Gly Leu
 690 695 700
 Ser Ile Glu Glu Tyr Lys Thr Thr Leu Lys Ile Ile Lys Gln Ala Ile
 705 710 715 720

WO 94/28144

PCT/US94/06066

-61-

Leu Ala Thr Asp Leu Ala Leu Tyr Ile Lys Arg Arg Gly Glu Phe Phe
725 730 735

Glu Leu Ile Arg Lys Asn Gln Phe Asn Leu Glu Asp Pro His Gln Lys
740 745 750

Glu Leu Phe Leu Ala Met Leu Met Thr Ala Cys Asp Leu Ser Ala Ile
755 760 765

Thr Lys Pro Trp Pro Ile Gln Gln Arg Ile Ala Glu Leu Val Ala Thr
770 775 780

Glu Phe Phe Asp Gln Gly Asp Arg Glu Arg Lys Glu Leu Asn Ile Glu
785 790 795 800

Pro Thr Asp Leu Met Asn Arg Glu Lys Lys Asn Lys Ile Pro Ser Met
805 810 815

Gln Val Gly Phe Ile Asp Ala Ile Cys Leu Gln Leu Tyr Glu Ala Leu
820 825 830

Thr His Val Ser Glu Asp Cys Phe Pro Leu Leu Asp Gly Cys Arg Lys
835 840 845

Asn Arg Gln Lys Trp Gln Ala Leu Ala Glu Gln Gln Glu Lys Met Leu
850 855 860

Ile Asn Gly Glu Ser Gly Gln Ala Lys Arg Asn
865 870 875

WO 94/28144

-62-

PCT/US94/06066

Applicant's or agent's file reference number	32083	International application No.
		PCT/US 94/06066

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>5</u> lines <u>6-9</u>	
B. IDENTIFICATION OF DEPOSIT	
Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 US	
Date of deposit 4 May 1993	Accession Number ATCC 69296
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
"In respect of those designations in which a European patent is sought, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 23(4) EPC)."	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
EP	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only	
<input checked="" type="checkbox"/> This sheet was received with the international application	
Authorized officer Doris L. Brock <i>DLB</i> PCT International Division	
For International Bureau use only	
<input type="checkbox"/> This sheet was received by the International Bureau on:	
Authorized officer	

WO 94/28144

PCT/US94/06066

-63-

CLAIMS

1. A purified and isolated polynucleotide encoding cGB-PDE.
2. The polynucleotide of claim 1 which is a DNA sequence.
3. The DNA sequence of claim 2 which is a cDNA sequence or a biological replica thereof.
4. The DNA sequence of claim 2 which is a genomic DNA sequence or a biological replica thereof.
5. An RNA transcript of the genomic DNA sequence of claim 4.
6. The DNA sequence of claim 2 which is a wholly or partially chemically synthesized DNA sequence or a biological replica thereof.
7. The DNA sequence of claim 4 further comprising an endogenous expression control DNA sequence.
8. A DNA vector comprising a DNA sequence according to claim 2.
9. The vector of claim 8 wherein said DNA sequence is operatively linked to an expression control DNA sequence.
10. A host cell stably transformed or transfected with a DNA sequence according to claim 7 in a manner allowing the expression in said host cell of cGB-PDE polypeptide possessing a ligand/receptor binding biological activity or immunological property specific to cGB-PDE.

WO 94/28144

PCT/US94/06066

-64-

11. A method for producing cGB-PDE polypeptide, said method comprising growing a host cell according to claim 10 in a suitable nutrient medium and isolating cGB-PDE polypeptide from said cell or the medium of its growth.

12. A polypeptide or peptide capable of specifically binding to cGB-PDE.

13. An antibody substance according to claim 12.

14. A monoclonal antibody according to claim 13.

15. A hybridoma cell line producing a monoclonal antibody according to claim 14.

16. A humanized antibody substance according to claim 13.

17. An antisense polynucleotide specific for a polynucleotide encoding cGB-PDE.

18. A DNA sequence encoding cGB-PDE and selected from the group consisting of:

- (a) the DNA sequence set out in SEQ ID NO: 9 or 22;
- (b) a DNA which hybridizes under stringent conditions to the DNA of (a); and
- (c) a DNA sequence which, but for the redundancy of the genetic code, would hybridize under stringent conditions to a DNA sequence of (a) or (b).

WO 94/28144

PCT/US94/06066

1 / 10

CGB-PDE	FOMKHEVILCK	WILSVKKNYR	K. NVAYHNWR	HAFNTAQCMF	AALKAGKIQK
ROS- α	FHIPOEALVR	FMYSLSKGYR	R.. ITYHNWR	HGFNVGQTMF	SLVTGKLKR
ROS- β	FQIPOEVLVR	FLFSVSKGYR	R.. ITYHNWR	HGFNVQTMF	TLLMTGKLKS
CONE- α	FKVPEVILTR	WMTYVRKGYR	A.. VTYHNWR	HGFNVQTMF	TLLMTGRLKK
CGS	YKIDCPTLAR	FCLMVKKGYR	D.P. PYHNM	HAFSYSHFCY	LLYKNLLELTN
61	KCAM	FKIPVSCLIA	FAEALLEGVYS	KYKPNPYHNLI	HAADVQTQVH
63	KCAM	FKIPTVFLMT	FLDALETGYG	KYKPNPYHNQI	HAADVQTQVH
RATDUNCE	FQIPADTLR	YLLTLEGHYH	S. NVAYHNSI	HAADVQOSAH	VLLGTPALEA
DROSDUNCE	.MIPPKTFLN	FMSSTLEDHYV	K. DNPFHNSL	HAADVQTQSTN	VLLNTPALEG
CONSERVED	-----*	-----*	Y- -----*	H-----*	-----*-----*
CGB-PDE	RLTDLEILAL	LLAALSHDLD	HRGYNNSYIQ	RSEHPLAOLY	CH.. SIMEHH
ROS- α	YFTDLEALAM	VTAAFCHDID	HRGTNNLYQM	KSQNPLAKLH	GS.. SILERH
ROS- β	YYTDLLEAFAM	VTAGLCHDID	HRGTNNLYQM	KSQNPLAKLH	GS.. SILERH
CONE- α	YYTDLLEAFAM	LAAAFCHDID	HRGTNNLYQM	KSTSPLARLH	GS.. SILERH
CGS	YLEDMEIFAL	FISCMCHDLD	HRGTNNSFQV	ASKSVLAALY	SSEGSMVERH
61	KCAM	WLTELEILAM	HIGTTNNFHI	QTRSDVAILY	.NDRSVLENH
63	KCAM	CLESIEVLAI	YFAAAIHDYE	HIGTTNSFHI	QTKSEQAILY
RATDUNCE	VFTDLEVLAA	IFAAAIHDYE	HIGTTNSFHI	.NDRSVLENH	
DROSDUNCE	VFTPLLEVGGAA	IFACAIHDVD	HPGVSNQFLI	NTNSELALMY	
CONSERVED	-----E-----	-----*	HPGLTQNQFLY	NSSSELALMY	.NDESVLENH
					H-G--N-*-----A-----S-E-H

FIGURE 1A

CGB-PDE	CGB-PDE
ROS- α	ROS- α
ROS- β	ROS- β
CONE- α ,	CONE- α ,
CGS	CGS
61 KCAM	61 KCAM
63 KCAM	63 KCAM
RATDUNC	RATDUNC
DROSDUNC	DROSDUNC
CONSERVE	CONSERVE

WO 94/28144

2 / 10

PCT/US94/06066

FIGURE 1B

WO 94/28144

PCT/US94/06066

3 / 10

812 778
776 776
776 776
844

QRQIAELVAT	EFFDQGDRER	KELNIEPADL	MNREKKNKIP	SMQVGFID..
OSKVALLVAA	ERWEQDLER	TVLQQNPIPM	MDRNKADEL	KLQVGFID..
OSKVALLVAA	EFWEQDLER	TVLDOQPIPM	MDRNKAELP	KLQVGFID..
OSQVALLVAN	EFWEQDLER	TVLQQQPIPM	MDRNKKDEL	KLQVGFID..
CGS	EFFSQGDLEK	A.MGNRPMEM	MDREKAY.	IP ELOISFME..
61	HHRWTTMALME	EL.. GLPFSP	LCDRKSTWVA	QSQIGFID..
63	HSRWTTKALME	EL.. GLPFSP	LCDRTSTLVA	QSQIGFID..
RATDUNCE	EFFFQGDRER	ES.. GLDISP	MCDKHTASYE	KSQVGFID..
DROSDUNCE	EFFLQGDKER	ES.. GMDISP	MCDRHNATIE	KSQVGFID..
CONSERVED	EF--QGD-E--	--Q--F--	--Q--F--	--Q--F--

*-----**--

CGB-PDE
ROS- α
ROS- β
CONE- α'
CGS
61 KCAM
63 KCAM
RATDUNCE
DROSDUNCE
CONSERVED

FIGURE 1C

WO 94/28144

4 / 1 0

PCT/US94/06066

CGB-PDE	LLELYKDISS	HLDVTALCHK	IFLHITHGLIS	ADRYSLFLYVC	EDSSNDKFLI	188
CGS	ILQLOCELYD	LDASSLQLK	VLOYLQOETQ	ASRCCLLVS	EDN..LQ..LS	245
CONE- α	LLEVL..LEE	AGSVELAAGR	ALORLAQLQ	ADRCMSMFLCR	ARNGTPE..VA	106
ROS- β	LFELYQDMQE	NYNMRWVFK	ILRRLCSILH	ADRCSLFLYR	QRNGVAE..LA	107
ROS- α	..LLRDFD	NLOAEKCVFN	VMKKLCFLQ	ADRMSSLFLYR	ARNGIAE..LA	109
CONSERVED	-----	-----	-----	A-R-----	-----	-----
CGB-PDE	SRLFDVAEGS	TLEE...ASN	NCIRLEWNKG	IVGHVAAGFE	PLNIKDAYED	237
CGS	CKVIG..DK	VLEE..	EISFPLLTG	RLGQYVEDKK	SIQLKDLTSE	292
CONE- α	SKLLDVTPTS	KFEDNLVVPD	REAVFPLDVG	IVGWVAHTKK	TFNVPDVKKN	154
ROS- β	TRLFSVQPD	VLEDCLVPPD	SEIVFPLDVG	IVGHVAQTKK	MVNQDVMEC	155
ROS- α	TRLFNVHKDA	VLEECLVAPD	SEIVFPLDVG	VVGHVALSKK	IVNVPNTED	157
CONSERVED	-----	-----	E-----	G-----G-V-----G	-----	-----
CGB-PDE	PRFNAEVQDQI	TGYKTOSILC	MPIKNHR..EE	VVGVAQAINK	KSGNGGTFTE	287
CGS	DM..QOLOSM	LGCEYQAMLC	VPVISRATDQ	VVALACAFNK	LGDDLFTD	342
CONE- α	SHFSDFMDKQ	TGYVTRNLLA	TPIV..MGKE	VLAVFMAVNK	VDASEFSK	204
ROS- β	PHFSSFADEL	TDYVTRNLLA	TPIM..NGKD	VVAVIMAVNK	LDGPCFTS	205
ROS- α	EHFCDFVDTL	TEYQTKNLLA	SPIM..NGKD	VVATIMAVNK	VDGPHFTF	207
CONSERVED	-----	-----	L-----P-----L-----	V-----A-NK-----F-----	-----	-----

FIGURE 2A

WO 94/28144

5 / 1 0

PCT/US94/06066

CGB-PDE	KDEKDFAYL	AFCGIVLHNA	QIYETSLLEN	KRNQVLLDA	SLJFEEQQLSL	337
CGS	QDEHVIIQHCF	HYTSTVLTST	LAFOKEQQLK	CFCOALLOVA	KNLFTHLDLV	390
CONE- α	QDEEVFSKYL	SFVSIILKLH	HTNYLYNIES	RRSQILMWSA	NKVFEELTDV	252
ROS- β	EDEDVFLKYL	NFGTLNLKTY	HYSYLNHCET	RRGQVLLWSA	NKVFEELTDI	253
ROS- α	NDEEILLYKL	NFANLIMKVF	HLSYLHNCET	RRGQVLLWSG	SKVFEELTDI	255
CONSERVED	-DE-----	-----	-----	-----	-----	-----
CGB-PDE	EVILKKIAAT	IISFMQVQKC	TIFIVD. EDC	SDSFSSVFM	ECEELEKSD	361
CGS	SVLLOEITTE	ARNLSNAEIC	SVFILID. .Q	NEVAKVFDG	GYILEDSEY	409
CONE- α	ERQFHKALEYT	VRTYLNCCRY	SIGLLDMTKE	KEFY. DEWPV	KPGEVEPYKG	301
ROS- β	ERQFHKAFTY	VRAYLNCCRY	SVGLLDMTKE	KEFF. DVWPV	LMGEAQAYS	302
ROS- α	ERQFHKALEYT	VRAFLNCCRY	SVGLLDMTKE	KEFF. DVWPV	LMGEAPPYAG	304
CONSERVED	-----	-----	-----	-----	-----	-----
CGB-PDE	ILTRE.....	411
CGS	PKTPDGREVI	FYKIIDYILH	EIRI. .	PADQ. .	GIAGHVATTG	459
CONE- α	PRTPDGREIL	FYKVIDYILH	GKEEIKVIPT	PPMDHWTLIS	GLPTYVAENG	351
ROS- β	PRTPDGREIN	FYKVIDYILH	GKEDIKVIPT	PPADHWAIS	GLPTYVAESG	352
ROS- α	PRTPDGREIN	FYKVIDYILH	GKEDIKVIPT	PPPDDHWAIS	GLPTYVAQNG	354
CONSERVED	-----	-----	-----	-----	-----	-----

FIGURE 2B

WO 94/28144

PCT/US94/06066

CGB-PDE	EPLNIPDVSK	DKRFPWTTNEN	MGNINQQCIR	SLICTPIKNG	KKMKVIGVQ	459
CGS	QILNIPDAYA	HPLFY . RGV	DDSTGRF . TR	NILCFPIKN.	ENQEIVGVAE	499
CONE- α '	FICNMLNAPA	DEYFTFQKGP	VDETTGFW . IK	NVLSLPIWN.	KKEDIVGVAT	399
ROS- β	FICNIMNAPA	DEMNFQEQGP	LDDSGWI . YK	NVLSMPIWN.	KKEEIVGVAT	400
ROS- α	LICNIMNAPS	EDFFAFQKEP	LDESGWM . IK	NVLSMPIWN.	KKEEIVGVAT	402
CONSERVED	--N-----F-----	--L-----F-----	--L-----N-----	--L-----PI-N-----	--GV-----	--
CGB-PDE	LYNKMEETTG	KVKAFNRNDE	QFLEAFVIFC	GLGIQONTMY	EAVERAMAKQ	506
CGS	LYNKING...	PWFSKFDE	DLATAFSIYC	GISIAHSLLY	KKVNEAQYRS	541
CONE- α '	FYNRKDG...	KPFDEYDE	HIAETLTQFL	GWSLLNTDTY	EKMNKLENRK	441
ROS- β	FYNRKDG...	KPFDEODE	YLMESLTQFL	GWSVLNTDTY	DKMNKLENRK	442
ROS- α	FYNRKDG...	KPFDEMDE	TIMEslaQFL	GWSVLNPDTY	ELMNKLENRK	444
CONSERVED	--N-----F-----	--F-----DE-----	--F-----DE-----	--G-----Y-----	--G-----Y-----	--
CGB-PDE	WTLEVLSYH	ASAAEEEE				526
CGS	HLANEMMMYH	MKVSDDE				561
CONE- α '	DIAQEMILMNH	TKATPDE				461
ROS- β	DIAQDMVLYH	VRCDREE				462
ROS- α	DIFQDMVKYH	VKCDNEE				464
CONSERVED	--H-----E-----	--H-----E-----				

6 / 10

FIGURE 2C

WO 94/28144

PCT/US94/06066

7 / 10

A A A A A B B B B B

CCGB-PDE	CCGB-PDE
RROS- α	RROS- α
RROS- β	RROS- β
CONE- α	CONE- α
CGS	CGS

A A A A A B B B B B B

CGB-PDE	CGS
ROS- α	CONE- α
ROS- β	CGS
	CGB-PDE
	ROS- α
	ROS- β
	CONE- α
	CGS
	CONSERV

FIGURE 3

WO 94/28144

PCT/US94/06066

8 / 10




FIGURE 4

WO 94/28144

9 / 10

PCT/US94/06066





FIGURE 6

WO 94/28144

10 / 10

PCT/US94/06066




FIGURE 7




FIGURE 8

INTERNATIONAL SEARCH REPORT

Int. Application No.
PCT/US 94/06066

A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 C12N15/55 C12N9/16 C12P21/08 C12N15/11

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 5 C12N C12P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>JOURNAL OF BIOLOGICAL CHEMISTRY., vol.265, no.25, 5 September 1990, BALTIMORE US pages 14971 - 14978 THOMAS ETAL. 'Substrate- and Kinase-directed regulation of Phosphorylation of a cGMP-binding Phosphodiesterase by cGMP.' cited in the application see the whole document</p> <p>---</p> <p>-/-</p>	1-18

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *B* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

1

Date of the actual completion of the international search

26 September 1994

Date of mailing of the international search report

19.10.94

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentiaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax (+31-70) 340-3016

Authorized officer

Cupido, M

INTERNATIONAL SEARCH REPORT

Int'l	Application No
PCT/US 94/06066	

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	JOURNAL OF BIOLOGICAL CHEMISTRY., vol.265, no.25, 5 September 1990, BALTIMORE, MD US pages 14964 - 14970 THOMAS ET AL. 'Characterization of a Purified Bovine Lung cGMP-binding cGMP Phosphodiesterase' cited in the application see the whole document ---	1-18
Y	JOURNAL OF BIOLOGICAL CHEMISTRY., vol.267, no.26, 15 September 1992, BALTIMORE US pages 18683 - 18688 REPASKE ET AL. 'A Polymerase Chain Reaction Strategy to Identify and Clone Cyclic Nucleotide Phosphodiesterase cDNAs' see the whole document ---	1-18
Y	JOURNAL OF BIOLOGICAL CHEMISTRY., vol.266, no.26, 15 September 1991, BALTIMORE US pages 17655 - 17661 SONNENBURG ET AL. 'Molecular Cloning of a Cyclic GMP-stimulated Cyclic Nucleotide Phosphodiesterase cDNA' see the whole document ---	1-18
Y	GENOMICS, vol.13, no.3, July 1992 pages 698 - 704 COLLINS ET AL. 'The human Beta-Subunit of Rod Photoreceptor cGMP Phosphodiesterase: Complete Retinal cDNA Sequence and Evidence for Expression in Brain' cited in the application see the whole document ---	1-18
P,X	JOURNAL OF BIOLOGICAL CHEMISTRY., vol.268, no.30, 25 October 1993, BALTIMORE US pages 22863 - 22873 MCALLISTER-LUCAS ET AL. 'The Structure of a Bovine Lung cGMP-binding, cGMP-specific Phosphodiesterase Deduced from a cDNA Clone' see the whole document ---	1-18